皮膚科臨床アセット　10　ここまでわかった乾癬の病態と治療

出版社： 中山書店
著者：
発行日： 2012-06-08
分野： 臨床医学：内科  >  皮膚科
ISBN： 9784521733470
シリーズ： 皮膚科臨床アセット
電子書籍版： 2012-06-08 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

15,400 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

15,400 円(税込)

購入する

商品紹介

乾癬は皮膚科における重要疾患の１つであり，治療に難渋する疾患です。最近，生物学的製剤が次々に承認され，治療の幅も広がりました。本書では乾癬の病態について，新知見を含め詳述し，それぞれの病態に基づいた治療の組み立て方を解説．治療については，外用薬による局所療法から内服療法，そして生物学的製剤，さらに紫外線療法や温泉療法まで網羅しました。皮膚科医必携の一冊。

目次

  • 皮膚科臨床アセット 10 ここまでわかった乾癬の病態と治療

    ―目次―

    1．疫学・病因・病態・病理
    2．症状・診断・鑑別診断
    3．悪化誘因・合併症
    4．治療
    5．社会的対応

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 疫学・病因・病態・病理

P.2 掲載の参考文献
1) Rahman P, Gladman DD, Schentag CT, et al. Excessive paternal transmission in psoriatic arthritis. Arthritis Rheum 1999 ; 42 : 1228-31.
PubMed
1) Kawada A, Tezuka T, Nakamizo Y, et al. The Japanese Society for Psoriasis Research. A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci 2003 ; 31 : 59-64.
PubMed
2) Takahashi H, Nakamura K, Kaneko F, et al. Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002-2008. J Dermatol 2011 ; 38 : 1125-9.
PubMed
3) 飯塚一. 乾癬治療のピラミッド計画. 日皮会誌 2006 ; 116 : 1285-93.
 
4) Takahashi H, Takahashi I, Tsuji H, et al. Analysis of psoriatic patients registered in Asahikawa Medical College Hospital from 1983 to 2007. J Dermatol 2009 ; 36 : 632-7.
PubMed
5) 古江増隆, 山崎雙次, 神保幸一, ほか. 本邦における皮膚科受診患者の多施設横断四季別全国調査. 日皮会誌 2009 ; 119 : 1795-809.
 
6) Takahashi H, Tsuji H, Takahashi I, et al. Prevalence of obesity/adiposity in Japanese psoriasis patients : adiposity is correlated with the severity of psoriasis. J Dermatol Sci 2009 ; 54 : 61-3.
 
P.6 掲載の参考文献
1) Kawada A, Tezuka T, Nakamizo Y, et al. A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci 2003 ; 31 : 59-64.
PubMed
2) Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica 1974 ; 148 : 1-18.
PubMed
3) 小澤明. 乾癬 疫学・統計. 山村雄一, ほか編. 現代皮膚科学大系 4B. 角化異常性疾患 II. 東京 : 中山書店 ; 1981. pp3-11.
 
4) Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol 2000 ; 17 : 174-8.
 
5) Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol 1974 ; 109 : 207-11.
PubMed
6) Brandrup F, Hauge M, Henningsen K, et al. Psoriasis in an unselected series of twins. Arch Dermatol 1978 ; 114 : 874-8.
 
7) Duffy DL, Spelman LS, Martin NG. Psoriasis in Australian twins. J Am Acad Dermatol 1993 ; 29 : 428-34.
PubMed
8) 小澤明, 大城戸宗男, 猪子英俊. 乾癬の疾患遺伝子. 皮膚病診療 1997 ; 19 : 901-6.
 
9) Henseler T, Christophers E. Psoriasis of early and late onset : characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985 ; 13 : 450-6.
PubMed
10) Oka A, Tamiya G, Tomizawa M, et al. Association analysis using refined microsatellite markers localizes a susceptibility locus for psoriasis vulgaris within a 111 kb segment telomeric to the HLA-C gene. Hum Mol Genet 1999 ; 8 : 2165-70.
 
11) Balendran N, Clough RL, Arguello R, et al. Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3. J Invest Dermatol 1999 ; 113 : 322-8.
 
12) Nair RP, Stuart P, Henseler T, et al. Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet 2000 ; 66 : 1833-44.
PubMed
13) Veal CD, Capon F, Allen MH, et al. Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. Am J Hum Genet 2002 ; 71 : 554-64.
PubMed
14) 小澤明. 尋常性乾癬における主要組織適合抗原-II. DR (D related) 抗原の解析. 日皮会誌 1978 ; 88 : 981-92.
 
15) Mabuchi T, Oka A, Iizuka M, et al. Fine mapping of a psoriasis-susceptibility locus within the HLA class II region by using microsatellite markers in an association study of Japanese cases and controls. Tokai J Exp Clin Med 2007 ; 32 : 6-13.
 
16) Capon F, Munro M, Barker J, et al. Searching for the major histocompatibility complex psoriasis susceptibility gene. J Invest Dermatol 2002 ; 118 : 745-51.
 
17) Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008 ; 4 : e1000041.
 
18) Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009 ; 41 : 199-204.
PubMed
19) Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010 ; 42 : 985-90.
 
20) Ellinghaus E, Ellinghaus D, Stuart PE, et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 2010 ; 42 : 991-5.
PubMed
21) Huffmeier U, Uebe S, Ekici AB, et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 2010 ; 42 : 996-9.
PubMed
22) Stuart PE, Nair RP, Ellinghaus E, et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 2010 ; 42 : 1000-4.
PubMed
23) Sun L, Cheng H, Wang Z, et al. Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet 2010 ; 42 : 1005-9.
 
24) Riveira-Munoz E, He SM, Escaramis G, et al. Meta-analysis confirms the LCE3C_LCE3B deletion as a risk factor for psoriasis in several ethnic groups and finds interaction with HLA-Cw6. J Invest Dermatol 2011 ; 131 : 1105-9.
PubMed
25) Kulski JK, Kenworthy W, Bellgard M, et al. Gene expression profiling of Japanese psoriatic skin reveals an increased activity in molecular stress and immune response signals. J Mol Med 2005 ; 83 : 964-75.
PubMed
26) Matsuzaka Y, Okamoto K, Tsuji H, et al. Identification of the hRDH-E2 gene, a novel member of the SDR family, and its increased expression in psoriatic lesion. Biochem Biophys Res Commun 2002 ; 297 : 1171-80.
PubMed
27) Bowcock AM, Shannon W, Du F, et al. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet 2001 ; 10 : 1793-805.
PubMed
28) Oestreicher JL, Walters IB, Kikuchi T, et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J 2001 ; 1 : 272-87.
PubMed
29) Zhou X, Krueger JG, Kao MC, et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003 ; 13 : 69-78.
PubMed
30) Nomura I, Gao B, Boguniewicz M, et al. Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis : a gene microarray analysis. J Allergy Clin Immunol 2003 ; 112 : 1195-202.
PubMed
P.11 掲載の参考文献
1) Meenan FOC. A note on the history of psoriasis. Ir J Med Sci 1955 ; 351 : 141-2.
 
2) Weinstein GD, Van Scott EJ. Autoradiographic analysis of turnover times of normal and psoriatic epidermis. J Invest Dermatol 1965 ; 45 : 257-62.
PubMed
3) Voorhees JJ, Marcelo CL, Duell EA. Cyclic AMP, cyclic GMP, and glucocorticoids as potential metabolic regulators of epidermal proliferation and differentiation. J Invest Dermatol 1975 ; 65 : 179-90.
PubMed
4) Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999 ; 155 : 145-58.
PubMed
5) Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T (H) 17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007 ; 445 : 648-51.
 
6) Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007 ; 445 : 866-73.
PubMed
7) Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009 ; 361 : 496-509.
PubMed
P.14 掲載の参考文献
1) Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases : potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010 ; 130 : 1785-96.
PubMed
2) Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994 ; 180 : 1141-6.
PubMed
3) Weinstein GD, McCullough JL, Ross PA. Cell kinetic basis for pathophysiology of psoriasis. J Invest Dermatol 1985 ; 85 : 579-83.
PubMed
4) Han G, Williams CA, Salter K, et al. A role for TGFbeta signaling in the pathogenesis of psoriasis. J Invest Dermatol 2010 ; 130 : 371-7.
 
5) Takahashi H, Tsuji H, Hashimoto Y, et al. Cell proliferation and cytokine induction by TNF-alpha of psoriatic keratinocytes are not different from normal keratinocytes in vitro. Indian J Dermatol 2009 ; 54 : 237-9.
 
6) Komine M, Rao LS, Kaneko T, et al. Inflammatory versus proliferative processes in epidermis. Tumor necrosis factor alpha induces K6b keratin synthesis through a transcriptional complex containing NFkappa B and C/EBPbeta. J Biol Chem 2000 ; 275 : 32077-88.
 
7) Wei L, Debets R, Hegmans JJ, et al. IL-1 beta and IFN-gamma induce the regenerative epidermal phenotype of psoriasis in the transwell skin organ culture system. IFN-gamma up-regulates the expression of keratin 17 and keratinocyte transglutaminase via endogenous IL-1 production. J Pathol 1999 ; 187 : 358-64.
PubMed
8) Shen Z, Wang G, Fan JY, et al. B1*04, *07-restricted epitopes on Keratin 17 for autoreactive T cells in psoriasis. J Dermatol Sci 2005 ; 38 : 25-39.
 
9) Depianto D, Kerns ML, Dlugosz AA, et al. Keratin 17 promotes epithelial proliferation and tumor growth by polarizing the immune response in skin. Nat Genet 2010 ; 42 : 910-4.
 
10) Hohl D. Expression patterns of loricrin in dermatological disorders. Am J Dermatopathol 1993 ; 15 : 20-7.
PubMed
11) Kim BE, Leung DY, Boguniewicz M, et al. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol 2008 ; 12 : 332-7.
 
12) Yano S, Banno T, Walsh R, et al. Transcriptional responses of human epidermal keratinocytes to cytokine interleukin-1. J Cell Physiol 2008 ; 214 : 1-13.
PubMed
13) Komatsu N, Saijoh K, Kuk C, et al. Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis : dependence on phenotype, severity and therapy. Br J Dermatol 2007 ; 156 : 875-83.
PubMed
14) Morizane S, Yamasaki K, Kabigting FD, et al. Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D3, and retinoic acid. J Invest Dermatol 2010 ; 130 : 1297-306.
PubMed
15) Simon M, Tazi-Ahnini R, Jonca N, et al. Alterations in the desquamation-related proteolytic cleavage of corneodesmosin and other corneodesmosomal proteins in psoriatic lesional epidermis. Br J Dermatol 2008 ; 159 : 77-85.
PubMed
16) Oyama Z, Naoe Y, Kimura H, et al. New non-invasive method for evaluation of the stratum corneum structure in diseases with abnormal keratinization by immunofluorescence microscopy of desmoglein 1 distribution in tape-stripped samples. J Dermatol 2010 ; 37 : 873-81.
 
17) Kubo A, Nagao K, Yokouchi M, et al. External antigen uptake by Langerhans cells with reorganization of epidermal tight junction barriers. J Exp Med 2009 ; 206 : 2937-46.
 
18) Kirschner N, Poetzl C, von den Driesch P, et al. Alteration of tight junction proteins is an early event in psoriasis : putative involvement of proinflammatory cytokines. Am J Pathol 2009 ; 175 : 1095-106.
PubMed
19) Watson RE, Poddar R, Walker JM, et al. Altered claudin expression is a feature of chronic plaque psoriasis. J Pathol 2007 ; 212 : 450-8.
PubMed
20) Lucke T, Choudhry R, Thom R, et al. Upregulation of connexin 26 is a feature of keratinocyte differentiation in hyperproliferative epidermis, vaginal epithelium, and buccal epithelium. J Invest Dermatol 1999 ; 112 : 354-61.
PubMed
21) Tacheau C, Laboureau J, Mauviel A, et al. TNF-alpha represses connexin43 expression in HaCat keratinocytes via activation of JNK signaling. J Cell Physiol 2008 ; 216 : 438-44.
PubMed
22) Valins W, Amini S, Berman B. The Expression of Toll-like receptors in dermatological diseases and the therapeutic effect of current and newer topical Toll-like receptor modulators. J Clin Aesthet Dermatol 2010 ; 3 : 20-9.
PubMed
23) Miller LS, Sorensen OE, Liu PT, et al. TGF-alpha regulates TLR expression and function on epidermal keratinocytes. J Immunol 2005 ; 174 : 6137-43.
PubMed
24) Nestle FO, Di Meglio P, Qin JZ, et al. Skin immune sentinels in health and disease. Nat Rev Immunol 2009 ; 9 : 679-91.
PubMed
25) Timar KK, Dallos A, Kiss M, et al. Expression of terminal complement components by human keratinocytes. Mol Immunol 2007 ; 44 : 2578-86.
 
26) Sano S, Chan KS, Carbajal S, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005 ; 11 : 43-9.
 
27) Sestito R, Madonna S, Scarponi C, et al. STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation. FASEB J 2011 ; 25 : 916-27.
 
P.20 掲載の参考文献
1) 戸倉新樹. 乾癬発症の引き金としての微生物. 飯塚一, 編. 皮膚科診療プラクティス 16. 乾癬にせまる. 東京 : 文光堂 ; 2004. pp56-60.
 
2) Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999 ; 155 : 145-58.
PubMed
3) Nograles KE, Zaba LC, Shemer A, et al. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. Allergy Clin Immunol 2009 ; 123 : 1244-52.
PubMed
4) Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 cells. Annu Rev Immunol 2009 ; 27 : 485-517.
PubMed
5) Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004 ; 199 : 125-30.
PubMed
P.26 掲載の参考文献
1) Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004 ; 22 : 531-62.
PubMed
2) Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007 ; 13 : 242-4.
PubMed
3) Buckner JH. Mechanisms of impaired regulation by CD4+ CD25+ FOXP3+ regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010 ; 10 : 849-85.
PubMed
4) Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+ CD25 high regulatory T cells in psoriasis : mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005 ; 174 : 164-73.
PubMed
5) Maeda A, Beissert S, Schwarz T, et al. Phenotypic and functional characterization of ultraviolet radiation-induced regulatory T cells. J Immunol 2008 ; 180 : 3065-71.
 
6) Shintani Y, Yasuda Y, Kobayashi K, et al. Narrowband ultraviolet B radiation suppresses contact hypersensitivity. Photodermatol Photoimmunol Photomed 2008 ; 24 : 32-7.
PubMed
7) Shintani Y, Morita A. (in submission)
 
8) Lo YH, Torii K, Saito C, et al. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. J Dermatol Sci 2010 ; 58 : 225-7.
PubMed
9) Saito C, Maeda A, Morita A. Bath-PUVA therapy induces circulating regulatory T cells in patients with psoriasis. J Dermatol Sci 2009 ; 53 : 231-3.
PubMed
10) 齋藤稚代, 森田明理. ナローバンドUVB治療の実際-乾癬. MB Derma 2010 ; 172 : 11-5.
 
11) Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med 2004 ; 200 : 277-85.
 
12) Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. J Exp Med 2007 ; 204 : 33-9.
 
13) Quaglino P, Ortoncelli M, Comessatti A, et al. Circulating CD4+ CD25bright FOXP3+ T cells are up-regulated by biological therapies and correlate with the clinical response in psoriasis patients. Dermatology 2009 ; 219 : 250-8.
 
14) Diluvio L, Romiti ML, Angelini F, et al. Infliximab therapy induces increased polyclonality of CD4+ CD25+ regulatory T cells in psoriasis. Br J Dermatol 2010 ; 162 : 895-7.
PubMed
15) Yan KX, Fang X, Han L, et al. Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs. guttate psoriasis vulgaris. Br J Dermatol 2010 ; 163 : 48-56.
PubMed
P.29 掲載の参考文献
1) 長岡功. 好中球機能の基礎. 皮膚アレルギーフロンティア 2008 ; 6 : 13-20.
Medical*Online
2) Terui T, Ozawa M, Tagami H. Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis : a neutrophil-associated inflammation-boosting loop. Exp Dermatol 2000 ; 9 : 1-10.
 
3) Griffin TD, Lattanand A, Van Scott EJ. Clinical and histological heterogeneity of psoriasis plaques. Arch Dermatol 1988 ; 124 : 216-20.
PubMed
4) 原弘之, 照井正. 乾癬と好中球. 皮膚アレルギーフロンティア 2008 ; 6 : 33-7.
Medical*Online
5) Terui T, Kato T, Tagami H. Stratum corneum activation of complement through the antibody-independent alternative pathway. J Invest Dermatol 1989 ; 92 : 593-7.
PubMed
6) Ozawa M, Terui T, Tagami H. Localization of IL-8 and complement components in lesional skin of psoriasis vulgaris and pustulosis palmaris et plantaris. Dermatology 2005 ; 211 : 249-55.
PubMed
7) Keller M, Spanou Z, Schaerli P, et al. T cell-regulated neutrophilic inflammation in autoinflammatory diseases. J Immunol 2005 ; 175 : 7678-786.
PubMed
8) 武井寛, 仙道富士郎. 好中球とapoptosis. MB Derma 2003 ; 75 : 8-14.
 
P.32 掲載の参考文献
1) Boehncke WH, Wortmann S, Kaufmann R, et al. A subset of macrophages located along the basement membrane ("lining cells") is a characteristic histopathological feature of psoriasis. Am J Dermatopathol 1995 ; 17 : 139-44.
 
2) Wang H, Peters T, Kess D, et al. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 2006 ; 116 : 2105-14.
 
3) Fuentes-Duculan J, Suarez-Farinas M, Zaba LC, et al. A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol 2010 ; 130 : 2412-22.
PubMed
4) Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trend Immunol 2004 ; 25 : 677-86.
PubMed
5) Mosser DM, Edwards JP. Exporing the full spectrum of macrophage activation. Nat Rev Immunol 2008 ; 8 : 958-69.
PubMed
6) Nestle FO, Di Meglio P, Qin JZ, et al. Skin immune sentinels in health and disease. Nat Rev Immunol 2009 ; 9 : 679-91.
PubMed
7) Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007 ; 204 : 3183-94.
PubMed
8) Zaba LC, Fuentes-Duculan J, Steinman RM, et al. Nomal human dermis contains distinct population of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. J Clin Invest 2007 ; 117 : 2517-25.
 
9) Wilson RW, Ballantyne CM, Smith CW, et al. Gene targeting yields a CD18-mutant mouse for study of inflammation. J Immunol 1993 ; 151 : 1571-8.
 
10) Bullard DC, Scharffetter-Kochanek K, McArther MJ, et al. A polygenic mouse model of psoriasiform skin disease in CD18-deficient mice. Proc Natl Acad Sci U S A 1996 ; 93 : 2116-21.
 
11) Quaglino P, Ortoncelli M, Comessatti A, et al. CD4+CD25 bright FOXP3+ T cells are up-regulated by biological therapies and correlate with the clinical response in psoriasis patients. Dermatology 2009 ; 219 : 250-8.
PubMed
P.36 掲載の参考文献
1) Jariwala SP. The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res 2007 ; 299 : 359-66.
PubMed
2) Zaba LC, Krueger JG, Lowes MA. Resident and "inflammatory" dendritic cells in human skin. J Invest Dermatol 2009 ; 129 : 302-8.
PubMed
3) Katz SI, Tamaki K, Sachs DH. Epidermal Langerhans cells are derived from cells originating in bone marrow. Nature 1979 ; 282 (5736) : 324-6.
PubMed
4) Ginhoux F, Tacke F, Angeli V, et al. Langerhans cells arise from monocytes in vivo. Nat Immunol 2006 ; 7 : 265-73.
PubMed
5) Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 2005 ; 102 : 19057-62.
PubMed
6) Elias AN, Nanda VS, Barr RJ. CD1a expression in psoriatic skin following treatment with propylthiouracil, an antithyroid thioureylene. BMC Dermatol 2003 ; 3 : 3.
PubMed
7) Deguchi M, Aiba S, Ohtani H, et al. Comparison of the distribution and numbers of antigen-presenting cells among T-lymphocyte-mediated dermatoses : CD1a+, factor XIIIa+, and CD68+ cells in eczematous dermatitis, psoriasis, lichen planus and graft-versus-host disease. Arch Dermatol Res 2002 ; 294 : 297-302.
PubMed
8) Komine M, Karakawa M, Takekoshi T, et al. Early inflammatory changes in the "perilesional skin" of psoriatic plaques : is there interaction between dendritic cells and keratinocytes? J Invest Dermatol 2007 ; 127 : 1915-22.
PubMed
9) Poulin LF, Henri S, de Bovis B, et al. The dermis contains langerin+ dendritic cells that develop and function independently of epidermal Langerhans cells. J Exp Med 2007 ; 204 : 3119-31.
PubMed
10) Bennett CL, van Rijn E, Jung S, et al. Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol 2005 ; 169 : 569-76.
PubMed
11) Yoshiki R, Kabashima K, Sugita K, et al. IL-10-producing Langerhans cells and regulatory T cells are responsible for depressed contact hypersensitivity in grafted skin. J Invest Dermatol 2009 ; 129 : 705-13.
PubMed
12) Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus : the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A 2002 ; 99 : 351-8.
PubMed
13) Zaba LC, Fuentes-Duculan J, Steinman RM, et al. Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. J Clin Invest 2007 ; 117 : 2517-25.
PubMed
14) Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 2007 ; 7 : 19-30.
 
15) Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009 ; 129 : 79-88.
PubMed
16) Zaba LC, Krueger JG, Lowes MA. Resident and "inflammatory" dendritic cells in human skin. J Invest Dermatol 2009 ; 129 : 302-8.
PubMed
17) Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, et al. Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol 2007 ; 119 : 1210-7.
PubMed
18) Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005 ; 202 : 135-43.
PubMed
19) Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007 ; 449 : 564-9.
PubMed
20) Guttman-Yassky E, Krueger JG. Psoriasis : evolution of pathogenic concepts and new therapies through phases of translational research. Br J Dermatol 2007 ; 127 : 2391-8.
 
21) Seneschal J, Milpied B, Vergier B, et al. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 2009 ; 161 : 1081-8.
PubMed
P.41 掲載の参考文献
1) Piskin G, Sylva-Steenland RMR, Bos JD, et al. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions : enhanced expression in psoriatic skin. J Immunol 2006 ; 176 : 1908-15.
PubMed
2) 飯塚一. 乾癬の病態 : TIP-DC-Th17細胞学説をめぐって. 皮膚アレルギーフロンテイア 2009 ; 7 : 7-11.
 
3) Liang LC, Tan XY, Luxenberg DP, et al. Interleukin (IL) -22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006 ; 203 : 2271-9.
 
4) Peric M, Koglin S, Kim S-M, et al. IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes. J Immunol 2008 ; 181 : 8504-12.
PubMed
5) Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T (H) 17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007 ; 445 : 648-51.
 
6) Guttman-Yassky E, Lowes MA, Fuentes-Ducalan J, et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 2008 ; 181 : 7420-7.
 
7) Yang XO, Panopoulos AD, Nurieva R, et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 2007 ; 282 : 9358-63.
PubMed
8) Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNAbinding domain of STAT3 cause hyper-IgE syndrome. Nature 2007 ; 448 : 1058-62.
PubMed
9) Minegishi Y, Saito M, Nagasawa M, et al. Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J Exp Med 2009 ; 206 : 1291-301.
PubMed
10) Koga C, Kabashima K, Shiraishi N, et al. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 2008 ; 128 : 2625-30.
PubMed
11) Nomura T, Akiyama M, Sandilands A, et al. Specific filaggrin mutations cause ichthyosis vulgaris and are significantly associated with atopic dermatitis in Japan. J Invest Dermatol 2008 ; 128 : 1436-41.
PubMed
P.44 掲載の参考文献
1) Schon MP. Animal models of psoriasis : a critical appraisal. Exp Dermatol 2008 ; 17 : 703-12.
PubMed
2) Gudjonsson JE, Johnston A, Dyson M, et al. Mouse models of psoriasis. J Invest Dermatol 2007 ; 127 : 1292-308.
PubMed
3) Schon MP. Animal models of psoriasis-what can we learn from them? J Invest Dermatol 1999 ; 112 : 405-10.
 
4) Nickoloff BJ. Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med 2006 ; 12 : 102-6.
PubMed
5) Sano S, Chan KS, Carbajal S, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005 ; 11 : 43-9.
 
6) Sano S, Chan KS, DiGiovanni J. Impact of Stat3 activation upon skin biology : a dichotomy of its role between homeostasis and diseases. J Dermatol Sci 2008 ; 50 : 1-14.
PubMed
7) Sano S, Itami S, Takeda K, et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. Embo J 1999 ; 18 : 4657-68.
 
8) Hertle MD, Kubler MD, Leigh IM, et al. Aberrant integrin expression during epidermal wound healing and in psoriatic epidermis. J Clin Invest 1992 ; 89 : 1892-901.
PubMed
9) Ortonne JP. Aetiology and pathogenesis of psoriasis. Br J Dermatol 1996 ; 135 (Suppl 49) : 1-5.
 
10) Piepkorn M, Pittelkow MR, Cook PW. Autocrine regulation of keratinocytes : the emerging role of heparin-binding, epidermal growth factor-related growth factors. J Invest Dermatol 1998 ; 111 : 715-21.
PubMed
11) Miyoshi K, Takaishi M, Nakajima K, et al. Stat3 as a therapeutic target for the treatment of psoriasis : a clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest Dermatol 2011 ; 131 : 108-17.
PubMed
12) Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009 ; 129 : 1339-50.
PubMed
13) Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes : a potential role in psoriasis. Eur J Immunol 2006 ; 36 : 1309-23.
PubMed
14) Boniface K, Bernard FX, Garcia M, et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005 ; 174 : 3695-702.
PubMed
15) Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007 ; 178 : 2229-40.
PubMed
16) Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T (H) 17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007 ; 445 : 648-51.
 
17) Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004 ; 199 : 125-30.
PubMed
18) Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007 ; 204 : 3183-94.
PubMed
19) Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007 ; 13 : 242-4.
PubMed
20) Nakajima K, Kanda T, Takaishi M, et al. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J Immunol 2011 ; 186 : 4481-9.
 
21) Song H, Wang R, Wang S, et al. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A 2005 ; 102 : 4700-5.
 
22) Swindell WR, Johnston A, Carbajal S, et al. Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. in psoriatic skin. J Immunol 2006 ; 176 : 1908-15.
 
P.50 掲載の参考文献
1) Gupta MA, Gupta AK, Kirby S, et al. Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. Arch Dermatol 1988 ; 124 : 1052-7.
 
2) Yosipovitch G, Goon A, Wee J, et al. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000 ; 143 : 969-73.
PubMed
3) 梅沢慶紀, 馬渕智生, 飯塚万利子, ほか. 乾癬の痒みとその治療について. 臨皮 2005 ; 59 : 203-5.
 
4) 高森建二. 痒みの機序. 玉置邦彦, ほか編. 最新皮膚科学大系 3. 湿疹 痒疹 掻痒症 紅皮症 蕁麻疹. 東京 : 中山書店 ; 2002. pp120-7.
 
5) Gutzmer R, Mommert S, Gschwandtner M, et al. The histamine H4 receptor is functionally expressed on T (H) 2 cells. J Allergy Clin Immunol 2009 ; 123 : 619-25.
 
6) Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris : comparative evaluation of itch-associated cutaneous factors. Br J Dermatol 2003 ; 149 : 718-30.
PubMed
7) Reich A, Orda A, Wisnicka B, et al. Plasma neuropeptides and perception of pruritus in psoriasis. Acta Derm Venereol 2007 ; 87 : 299-304.
PubMed
8) Chang SE, Han SS, Jung HJ, et al. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol 2007 ; 156 : 1272-7.
PubMed
9) Madej A, Reich A, Orda A, et al. Vascular adhesion protein-1 (VAP-1) is overexpressed in psoriatic patients. J Eur Acad Dermatol Venereol 2007 ; 21 : 72-8.
PubMed
10) Szepietowski JC, Reich A, Wisnicka B. Itching in patients suffering from psoriasis. Acta Dermatovenerol Croat 2002 ; 10 : 221-6.
PubMed
P.53 掲載の参考文献
1) Christophers E, Braun-Falco O. Mechanisms of parakeratosis. Br J Dermatol 1970 ; 82 : 268-75.
PubMed
1) Burks JW, Montgomery H. Histopathologic study of psoriasis. Arch Dermatol 1943 ; 48 : 479-93.
 
2) Ackerman AB. Sherlock Holmesian dermatopathology : parakeratosis as a diagnostic clue. Am J Surg Pathol 1978 ; 2 : 71-80.
PubMed
2) Pinkus H, Mehregan AH. The primary histologic lesion of seborrheic dermatitis and psoriasis. J Invest Dermatol 1966 ; 46 : 109-16.
PubMed
3) Cox AJ, Watson W. Histological variations in lesions of psoriasis. Arch Dermatol 1972 ; 106 : 503-6.
PubMed
4) Ragaz A, Ackerman AB. Evolution, maturation, and regression of lesions of psoriasis. Am J Dermatopathol 1979 ; 1 : 199-214.
PubMed
5) Barr RJ, Young EM. Psoriasiform and related papulosquamous disorders. J Cutan Pathol 1985 ; 12 : 412-25.
PubMed
6) Griffin TD, Lattanand A, VanScott EJ. Clinical and histologic heterogeneity of psoriatic plaques. Arch Dermatol 1988 ; 124 : 216-20.
PubMed
7) Lever WF, Lever GS. Psoriasis. In : Histopathology of the Skin. 7th ed. Philadelphia : J. B. Lippincott ; 1990. pp156-65.
 
8) Ackerman AB, Congchitnant N, Sanchez J, et al. Psoriasis. In : Histologic Diagnosis of Inflammatory Skin Diseases. 2nd ed. Baltimore : Williams & Wilkins ; 1997. pp663-73.
 
9) Gordon M, Johnson WC. Histopathology and histochemistry of psoriasis. 1. The active lesion and clinically normal skin. Arch Dermatol 1967 ; 95 : 402-7.
 
10) 西尾一方.細胞浸潤の様式. 皮膚と泌尿 1967 ; 29 (増刊号) : 927-38.
 
11) Ackerman AB, Jacobson M, Vitale P. Clue 7. In : Clues to Diagnosis in Dermatopathology. Chicago : ASCP Press ; 1991. pp25-8.
 
12) Weedon D. The psoriasiform reaction pattern. In : Skin Pathology. 2nd ed. Edinburgh : Churchil Livingstone ; 2002. pp75-96.
 
13) Iizuka H, Takahashi H, Ishida-Yamamoto A. Pathophysiology of generalized pustular psoriasis. Arch Dermatol Res 2003 ; 295 : s55-9.
PubMed
14) Kardaun SH, Kuiper H, Fidler V, et al. The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis. J Cutan Pathol 2010 ; 37 : 1220-9.
PubMed
15) Ackerman AB, Troy JL, Rosen LB, et al. Guttate psoriasis vs seborrheic dermatitis. In : Differential Diagnosis in Dermatopathology II. Philadelphia : Lea & Febiger ; 1988. pp2-5.
 
16) Soeprono FF. Histologic criteria for the diagnosis of pityriasis rubra pilaris. Am J Dermatopathol 1986 ; 8 : 277-83.
PubMed

II 症状・診断・鑑別診断

P.60 掲載の参考文献
1) Tiling-Gross S, Rees J. Assessment of area involvement in skin disease : a study using schematic figure outlines. Br J Dermatol 1993 ; 128 : 69-74.
 
2) Ashcroft DM, Wan Po AL, Williams HC, et al. Clinical measures of disease severity and outcome in psoriasis : a critical appraisal of their quality. Br J Dermatol 1999 ; 141 : 185-91.
PubMed
3) Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004 ; 51 : 563-9.
PubMed
4) Berth-Jones J, Grotzinger K, Rainville C, et al. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis : Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. Br J Dermatol 2006 ; 155 : 707-13.
 
5) van de Kerkhof PC. The Psoriasis Area and Severity Index and alternative approaches for the assessment of severity : persisting areas of confusion. Br J Dermatol 1997 ; 137 : 661-2.
PubMed
6) 岩月啓氏, 照井正, 小澤明, ほか. 膿疱性乾癬 (汎発型) 診療ガイドライン 2010 : TNFα阻害薬を組み入れた治療指針 (簡略版). 日皮会誌 2010 ; 120 : 815-39.
 
7) Both H, Essink-Bot ML, Busschbach J, et al. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 2007 ; 127 : 2726-39.
PubMed
P.64 掲載の参考文献
1) 小林仁. 乾癬患者のQOL. 飯塚一, 編. 皮膚科診療プラクティス16. 乾癬にせまる. 東京 : 文光堂 ; 2004. pp165-9.
 
2) 中川秀己, 五十嵐敦之, 江藤隆文, ほか. 乾癬における患者治療満足度調査 (第二報). 日皮会誌 2005 ; 115 : 1449-59.
 
3) 吉川邦彦. 乾癬, 乾皮症, 老人のかゆみの対策. 綜合臨牀 2004 ; 53 : 1718-22.
 
4) 須賀康, 池田志斈, 小川秀興, ほか. 尋常性乾癬の掻痒に対する第2世代抗ヒスタミン薬の効果. 西日皮膚 2005 ; 67 : 511-7.
 
5) Callen JP, Krueger GG, Lebwohl M, et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003 ; 49 : 897-9.
PubMed
6) Vardy D, Besser A, Amir M, et al. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol 2002 ; 147 : 736-42.
PubMed
7) Christopher SC, Feldman SR, Krueger G, et al. A 50 % reduction in the Psoriasis Area and Severity Index (PASI50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004 ; 50 : 859-66.
 
8) Sampogna F, Sera F, Abeni D, et al. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis : a cluster analysis. J Invest Dermatol 2004 ; 122 : 602-7.
PubMed
9) Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006 ; 298 : 309-19.
 
10) Feldman SR, Fleischer AB Jr, Reboussin DM, et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol 1996 ; 106 : 183-6.
PubMed
11) 中川秀己, 五十嵐敦之. 乾癬治療のQOL評価の重要性-患者の視点に立った治療のために. 日皮会誌 2005 ; 115 : 863-70.
 
12) McKenna SP, Doward LC, Whalley D, et al. Development of the PsAQoL : a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004 ; 63 : 162-9.
PubMed
13) 福地修, 中川秀己, 長谷川友紀, ほか. 乾癬特異的QOL指標Psoriasis Disability Index (PDI) 日本語版の開発と信頼性・妥当性の検討. 日皮会誌 2006 ; 116 : 1583-91.
 
14) Finlay AY, Kelly SE. Psoriasis - an index of disability. Clin Exp Dermatol 1987 ; 12 : 8-11.
PubMed
15) Lewis VJ, Finlay AY. Two decades experience of the Psoriasis Disability Index. Dermatology 2005 ; 210 : 261-8.
PubMed
16) 加藤則人. 日々の診療を楽しくするコミュニケーションスキル. 日本臨床皮膚科医会雑誌 2010 ; 27 : 296-8.
 
17) Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) -a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 ; 19 : 210-6.
 
18) 福原俊一, 編. 皮膚疾患のQOL評価-DLQI, Skindex29日本語版マニュアル. 東京 : 照林社 ; 2004.
 
19) Bronsard V, Paul C, Prey S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? J Eur Acad Dermatol Venereol 2010 ; 24 (Suppl 2) : 17-22.
 
20) Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005 ; 152 : 861-7.
PubMed
21) McKenna KM, Stern RS. The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. J Am Acad Dermatol 1997 ; 36 : 388-94.
 
22) Gelfand JM, Feldman SR, Stern RS, et al. Determinants of quality of life in patients with psoriasis : a study from the US population. J Am Acad Dermatol 2004 ; 51 : 704-8.
PubMed
23) Sampogna F, Tabolli S, Soderfeldt B, et al. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol 2006 ; 154 : 844-9.
PubMed
24) Sampogna F, Chren MM, Melchi CF, et al. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol 2006 ; 154 : 325-31.
PubMed
25) 福地修, 中川秀己. 患者QOL. 日皮会誌 2008 ; 118 : 2538-41.
 
26) Lundberg L, Johannesson M, Silverdahl M, et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000 ; 80 : 430-4.
 
27) Reich K, Kruger K, Mossner R, et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany : a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009 ; 160 : 1040-47.
 
28) Christophers E, Barker JN, Griffiths CE, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol 2010 ; 24 : 548-54.
PubMed
29) Touw CR, Hakkaart-Van Roijen L, Verboom P, et al. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001 ; 144 : 967-72.
PubMed
30) Billing E, McKenna SP, Staun M, et al. Adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) instrument for Sweden. Scand J Rheumatol 2010 ; 39 : 223-8.
PubMed
31) Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 ; 41 : 401-7.
PubMed
32) Ongenae K, Van Geel N, De Schepper S, et al. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol 2005 ; 152 : 1165-72.
PubMed
33) Harvima RJ, Viinamaki H, Harvima IT, et al. Association of psychic stress with clinical severity and symptoms of psoriatic patients. Acta Derm Venereol 1996 ; 76 : 467-71.
PubMed
34) Richards HL, Fortune DG, Weidmann A, et al. Detection of psychological distress in patients with psoriasis : low consensus between dermatologist and patient. Br J Dermatol 2004 ; 151 : 1227-33.
PubMed
35) Esposito M, Saraceno R, Giunta A, et al. An Italian study on psoriasis and depression. Dermatology 2006 ; 212 : 123-7.
 
36) Eghlileb AM, Davies EE, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol 2007 ; 156 : 1245-50.
 
P.71 掲載の参考文献
1) Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica 1974 ; 148 : 1-18.
PubMed
2) Kaur I, Handa S, Kumar B. Natural history of psoriasis : a study from the Indian subcontinent. J Dermatol 1997 ; 24 : 230-4.
PubMed
3) 安田秀美, 小林仁, 大河原章. 乾癬の社会的, 精神的影響に関する調査. 日皮会誌 1990 ; 100 : 1167-71.
 
4) 衛藤光. 完全寛解した乾癬7例の検討. 皮膚の科学 2004 ; 3 : 512-6.
 
5) 種井良二, 衛藤光, 西山茂夫. 乾癬のアンスラリン療法-ゲッケルマン療法, PUVA療法, UVB療法との治療効果の比較検討. 日皮会誌 1992 ; 102 : 369-76.
 
6) Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999 ; 45 : 51-9.
 
7) Dawe RS, Cameron H, Yule S, et al. A randomized controlled trial of narrowband ultraviolet B vs bath-psoralen plus ultraviolet A photochemotherapy for psoriasis. Br J Dermatol 2003 ; 148 : 1194-204.
 
8) Hodak E, Gottlieb AB, Segal T, et al. Climatotherapy at the Dead Sea is a remittive therapy for psoriasis : combined effects on epidermal and immunologic activation. J Am Acad Dermatol 2003 ; 49 : 451-7.
PubMed
9) Harari M, Novack L, Barth J, et al. The percentage of patients achieving PASI 75 after 1 month and remission time after climatotherapy at the Dead Sea. Int J Dermatol 2007 ; 46 : 1087-91.
PubMed
10) Eedy DJ, Burrows D, Bridges JM, et al. Clearance of severe psoriasis after allogenic bone marrow transplantation. BMJ 1990 ; 300 : 908.
PubMed
11) Jowitt SN, Yin JA. Psoriasis and bone marrow transplantation. BMJ 1990 ; 300 : 1398-9.
PubMed
12) Park BS, Youn JI. Factors influencing psoriasis : an analysis based upon the extent of involvement and clinical type. J Dermatol 1998 ; 25 : 97-102.
PubMed
13) Youn JI, Park BS, Park SB, et al. Characterization of early and late onset psoriasis in the Korean population. J Dermatol 1999 ; 26 : 647-52.
PubMed
14) Tanno M, Nakajima A, Ishiwata T, et al. Effect of general anesthesia on the abnormal immune response in patients with rheumatoid arthritis. Clin Exp Rheumatol 2004 ; 22 : 727-32.
PubMed
P.74 掲載の参考文献
1) Wittkower E. Psychological aspects of psoriasis. Lancet 1946 ; 1 : 566-9.
PubMed
2) Jeflliff SE, Evans E. Psoriasis as an hysterical conversion symbolization. New York Med J 1916 ; 104 : 1077-84.
 
3) Becker SW, Obermayer ME. Modern Dermatology and Syphilology. Philadelphia and London : J. B. Lippincott ; 1940.
 
4) Wittkower E. Psychological aspecs of dermatology. In : MacKenna RMB, editor. Modern Trends in Dermatology. New York : Paul B. Hoeber ; 1948. pp237-52.
 
5) Romano S. Psoriasis. Torino : Minerva Medica ; 1952.
 
6) Obermayer ME. VIII Miscellaneous Dermatoses with Psychic elements. In : Obermayer ME, editor. Psychocutaneous Medicine. Springfield : Thomas ; 1955. p305-79.
 
7) Susskind W, McGuire RJ. The emotional factor in psoriasis. Scot Med J 1959 ; 4 : 503-7.
PubMed
8) Goldsmith LA, Fisher M, Wacks J. Psychological characteristics of psoriatics. Implications for management. Arch Dermatol 1969 ; 100 : 674-6.
PubMed
9) Gilbert AR, Rodgers DA, Roenigk HH Jr. Personality evaluation in psoriasis. Cleve Clin Q 1973 ; 40 : 147-52.
PubMed
10) Farber EM, Bright RD, Nall ML. Psoriasis, a questionarie survey of 2144 patients. Arch Dermatol 1968 ; 98 : 248-59.
 
11) Seville RH. Psoriasis and stress II. Br J Dermatol 1978 ; 98 : 151-3.
PubMed
12) 猿田隆夫. 乾癬とストレス. 田上八朗, 編. 皮膚科MOOK 2. 乾癬と周辺疾患. 東京 : 金原出版 ; 1985. pp154-60.
 
13) Gaston L, Lassonde M, Bernier-Buzzanga J, et al. Psoriasis and stress : a prospective study. J Am Acad Dermatol 1987 ; 17 : 82-6.
 
14) Hardy GE, Cotterill JA. A study of depression and obsessionality in dysmorphophobic and psoriatic patients. Br J Psychiatry 1982 ; 140 : 19-22.
 
15) Farber EM, Lanigan SW, Rein G. The role of psychoimmunology in the pathogenesis of psoriasis. Cutis 1990 ; 46 : 314-6.
PubMed
16) Farber EM, Rein G, Lanigan SW. Stress and psoriasis : Psychoneuroimmunologic mechanisms. Int J Dermatol 1991 ; 30 : 8-12.
PubMed
17) Farber EM, Nail L. Psoriasis : a stress-related disease. Cutis 1993 ; 51 : 322-6.
 
18) Leichtman SR, Burnett JW, Robinson HM Jr. Body image concerns of psoriasis patients as reflected in human figure drawings. J Pers Assess 1981 ; 45 : 478-84.
PubMed
19) Gieler U, Ernst R, Fritz J. "My scale armor protects me"! The personality image and physical disability of psoriasis patients. Z Hautkr 1986 ; 61 : 572-6.
PubMed
20) Ginsburg IH, Link BG. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol 1989 ; 20 : 53-6.
PubMed
21) 小林美咲. 嗜癖的掻破行動が関連する皮膚疾患. 臨皮 2001 ; 55 (5 増) : 25-9.
 
22) Mazzetti M, Mozzetta A, Soavi GC, et al. Psoriasis, stress and psychiatry : psychodynamic characteristics of stressors. Acta Derm Venereol Suppl (Stockh) 1994 ; 186 : 62-4.
PubMed
23) Gupta MA, Gupta AK, Watteel GN. Early onset (< 40 years age) psoriasis is comorbid with greater psychopathology than late onset psoriasis : a study of 137 patient. Acta Derm Venereol 1996 ; 76 : 464-6.
PubMed
24) Masmoudi J, Maalej I, Masmoudi A, et al. Alexithymia and psoriasis : a case-control study of 53 patients. Encephale 2009 ; 35 : 10-7.
PubMed
25) Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007 ; 157 : 1249-51.
PubMed
26) Bahmer JA, Kuhl J, Bahmer FA. How do personality systems interact in patients with psoriasis, atopic dermatitis and urticaria? Acta Derm Venereol 2007 ; 87 : 317-24.
PubMed
27) Kilic A, Gulec MY, Gul U, et al. Temperament and character profile of patiets with psorisis. J Eur Acad Dermatol Venereol 2008 ; 22 : 537-42.
 
28) Kotrulja L, Tadinac M, Jakic-Begic N, et al. A multivariate analysis of clinical severity, psychological distress and psychopathological traits in psoriatic patients. Acta Derm Venereol 2010 ; 90 : 251-6.
 
29) Lobitz WC Jr. Chemistry and physiology of the skin. In : Ormsby OS, Mntgomery H, editors. Diseases of the Skin. 8th ed. Philadelphia : Lea and Febiger ; 1954. pp51-87.
 
30) 川本恭子. リエゾンコンサルテーション. Visual Dermatology 2005 ; 4 : 472-5.
 
P.80 掲載の参考文献
1) Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007 ; 370 : 263-71.
 
2) Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol 1988 ; 80 : 771-93.
 
3) Ohkawara A, Yasuda H, Kobayashi H, et al. Generalized pustular psoriasis in Japan : two distinct groups formed differences in symptoms and genetic background. Acta Derm Venereol 1996 ; 76 : 68-71.
PubMed
4) 上野賢一. 乾癬. 皮膚科学. 第7版. 京都 : 金芳堂 ; 2002. pp305-9.
 
5) 三橋善比古. 母斑と遺伝的モザイク. 皮膚臨床 2000 ; 42 : 835-40.
 
6) Happle R. New aspects of cutaneous mosaicism. J Dermatol 2002 ; 29 : 681-92.
PubMed
7) 佐々木千秋, 三橋善比古, 村井孝弥, ほか. 妊娠性無熱性膿疱性乾癬. 臨皮 1994 ; 48 : 1161-4.
 
P.87 掲載の参考文献
1) 飯塚一. 乾癬治療のピラミッド計画. 日皮会誌 2006 ; 116 : 1285-93.
 
2) 飯塚一. 乾癬. 玉置邦彦, 編. 最新皮膚科学大系 7. 角化異常性疾患. 東京 : 中山書店 ; 2002. pp191-205.
 
P.94 掲載の参考文献
1) von Zumbusch LR. Psoriasis und pustuloses Exanthem. Arch Dermatol Syph 1910 ; 99 : 335-46.
 
2) 岩月啓氏, 照井正, 小澤明, ほか. 膿疱性乾癬 (汎発型) 診療ガイドライン 2010. 日皮会誌 2010 ; 120 : 815-39.
 
3) 小宮根真弓. 乾癬の病態と治療 2008. 日皮会誌 2009 ; 119 : 863-71.
 
4) Muto M, Ohmura A, Hamamoto Y, et al. Generalized pustular psoriasis : strategy for identification of psoriasis susceptibility gene. Arch Dermatol Res 2003 ; 295 (Suppl 1) : S60-2.
 
5) 照井正. 膿疱性乾癬. 玉置邦彦, ほか編. 最新皮膚科学大系 6. 水疱症 膿疱症. 東京 : 中山書店 ; 2002. pp235-9.
 
6) 照井正. 掌蹠膿疱症. 玉置邦彦, ほか編. 最新皮膚科学大系 6. 水疱症 膿疱症. 東京 : 中山書店 ; 2002. pp226-31.
 
7) Kanekura T, Maruyama I, Kanzaki T, et al. Granulocyte and monocyte adsorption apheresis for pyoderma gangrenosum. J Am Acad Dermatol 2002 ; 47 : 320-1.
PubMed
8) Kanekura T, Yoshii N, Yonezawa T, et al. Treatment of pustular psoriasis with granulocyte and monocyte adsorption apheresis. J Am Acad Dermatol 2003 ; 49 : 329-32.
PubMed
P.99 掲載の参考文献
1) Scarpa R, Oriente P, Pulino A, et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984 ; 23 : 246-50.
 
2) Zachariae H. Prevalence of joint disease in patients with psoriasis : implications for therapy. Am J Clin Dermatol 2003 ; 4 : 441-7.
PubMed
3) Veale D, Rogers S, Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994 ; 33 : 133-8.
PubMed
4) Southwood TR, Petty RE, Malleson PN, et al. Psoriatic arthritis in children. Arthritis Rheum 1989 ; 32 : 1007-13.
PubMed
5) Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973 ; 3 : 55-78.
PubMed
6) Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990 ; 17 : 809-12.
PubMed
7) Bruce IN. Psoriatic arthritis : clinical features. In : Hochberg MC, et al. editors. Rheumatology. St. Louis : Mosby ; 2007. pp1165-75.
 
8) Kane D, Stafford L, Bresniham B, et al. A prospective, clinical and radiological study of early psoriatic arthritis : an early synovitis clinic experience. Rheumatology 2003 ; 42 : 146-8.
 
9) Gottlieb A, Korman NJ, Gordon KB, et al. Guideline of care for the management of psoriasis and psoriatic arthritis : Section 2. Psoriatic arthritis : overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008 ; 58 : 851-64.
PubMed
10) Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis. Arthritis Rheum 2006 ; 54 : 2665-73.
PubMed
P.108 掲載の参考文献
1) 清水宏. 紅皮症. あたらしい皮膚科学. 東京 : 中山書店 ; 2008. pp122-5.
 
1) Torii H, Nakagawa H. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol 2010 ; 59 : 40-9.
 
2) 飯塚一. 乾癬 臨床症状. 玉置邦彦, ほか編. 最新皮膚科学大系 7. 角化異常性疾患. 東京 : 中山書店 ; 2002. pp199-205.
 
3) 飯塚一. 乾癬 病態生理. 玉置邦彦, ほか編. 最新皮膚科学大系 7. 角化異常性疾患. 東京 : 中山書店 ; 2002. pp191-8.
 
4) 梅澤慶紀, 小澤明. 乾癬 治療. 玉置邦彦, ほか編. 最新皮膚科学大系 7. 角化異常性疾患. 東京 : 中山書店 ; 2002. pp219-31.
 
5) 大槻マミ太郎, 照井正, 小澤明, ほか. 乾癬におけるTNFα阻害薬の使用指針および安全対策マニュアル. 日皮会誌 2010 ; 120 : 163-71.
 
6) 相馬良直. 薬剤による紅皮症. 玉置邦彦, ほか編. 最新皮膚科学大系 3. 湿疹 痒疹 掻痒症 紅皮症 蕁麻疹. 東京 : 中山書店 ; 2002. pp155-8.
 
7) 藤山幹子. ウイルス感染症とdrug-induced hypersensitivity syndrome. 玉置邦彦, ほか編. 最新皮膚科学大系 15. ウイルス性疾患 性感染症. 東京 : 中山書店 ; 2003. pp195-9.
 
P.113 掲載の参考文献
1) 赤坂江美子, 馬渕智生, 小澤明ほか. 日本乾癬学会登録症例の集計-2009. 第24回日本乾癬学会記録集. 2009. pp86-7.
 
2) Ko HC, Jwa SW, Song M, et al. Clinical course of guttate psoriasis : long-term follow-up study. J Dermatol 2010 ; 37 : 894-9.
PubMed
3) 中山哲夫. 非ウイルス性感染症 レンサ球菌感染症の血清学的診断. 日本臨牀 2010 ; 68 (6月増刊号) : 135-7.
 
4) 飯塚一. 乾癬 臨床症状. 玉置邦彦, ほか編. 最新皮膚科学大系 7. 角化異常性疾患. 東京 : 中山書店 ; 2002. pp199-205.
 
5) 高橋英俊. Gibertばら色粃糠疹. 玉置邦彦, ほか編. 最新皮膚科学大系 7. 角化異常性疾患. 東京 : 中山書店 ; 2002. pp271-6.
 
6) 喜多野征夫. 類乾癬. 玉置邦彦, ほか編. 最新皮膚科学大系 7. 角化異常性疾患. 東京 : 中山書店 ; 2002. pp232-8.
 
7) 高原幹, 上田征吾, 東谷敏孝, ほか. 尋常性乾癬, アナフィラクトイド紫斑病, ベーチェット病等の扁桃病巣皮膚疾患における扁桃摘出術の有効性. 口咽科 2009 ; 22 : 43-7.
Medical*Online
P.117 掲載の参考文献
1) Willan R. On Cutaneous Diseases. London : J Johnson ; 1808.
 
2) Griffiths CE, Christophers E, Barker JN, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007 ; 156 : 258-62.
PubMed
3) Doring HF. Treatment of sebopsoriasis. A clinical trial-an etiological approach. Dermatologica 1984 ; 169 (Suppl 1) : 125-33.
 
4) Nakayama J. Four cases of sebopsoriasis or seborrheic dermatitis of the face and scalp successfully treated with 1a-24 (R) -dihydroxycholecalciferol (tacalcitol) cream. Eur J Dermatol 2000 ; 10 : 528-32.
PubMed
5) Li M, Messaddeq N, Teletin M, et al. Retinoid X receptor ablation in adult mouse keratinocytes generates an atopic dermatitis triggered by thymic stromal lymphopoietin. Proc Natl Acad Sci U S A 2005 ; 102 : 14795-800.
PubMed
6) Zaba LC, Suarez-Farinas M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009 ; 124 : 1022-10 e1-395.
PubMed
7) Doring HF. Studies of local treatment of psoriasis with a bifonazole-urea combination. Z Hautkr 1987 ; 62 : 894-6, 899-900.
 
P.120 掲載の参考文献
1) Tachau P. Problems of so-called infantile eczema. Acta Derm Venereol 1939 ; 20 : 232.
 
2) Warin PR, Faulkner KE. Napkin psoriasis. Br J Dermatol 1961 ; 73 : 445-7.
 
3) 斉藤隆三, 伊藤直子, 伊勢信子. 小児の乾癬ならびにNapkin psoriasisについて. 皮膚臨床 1973 ; 15 : 676-81.
 
4) 小笠原理雄, 梅林芳弘. Napkin psoriasis. 西日皮膚 1998 ; 60 : 761-2.
 
5) Skoven LG, Hjortshoj A. HLA-antigens and psoriasiform napkin dermatitis. Dermatologica 1978 ; 157 : 225-8.
 
6) 坪田晶子, 清水聡子, 加藤まどか, ほか. 乳児の乾癬性紅皮症-Napkin psoriasisで発症し紅皮症化した1例. 皮膚臨床 2004 ; 46 : 1719-22.
 
7) Jefferson J. Seborrheic dermatitis with moniliasis. Br J Dermatol 1967 ; 79 : 722-4.
PubMed
P.123 掲載の参考文献
1) Rich P, Scher RK. Nail psoriasis severity index : a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003 ; 49 : 206-12.
PubMed
2) Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail : anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007 ; 57 : 1-27.
 
3) Augstin M, Oglive A. Methods of outcomes measurement in nail psoriasis. Dermatology 2010 ; 221 (Suppl 1) : 23-8.
 
4) 東禹彦. 爪真菌症の鑑別診断. MB Derma 2006 ; 111 : 13-23.
 
5) Reich K, Ortonne JP, Kerkmann U, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis : a retrospective analysis of the EXPRESS Trial. Dermatology 2010 ; 221 : 172-8.
PubMed
6) Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010 ; 69 : 394-9.
PubMed
7) Parrish CA, Sobera JO, Elewski BE. Modification of the nail psoriasis severity index. J Am Acad Dermatol 2005 ; 53 : 745-6.
PubMed
8) Cassell SE, Bieber JD, Rich P, et al. The modified nail psoriasis index : validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007 ; 34 : 123-9.
PubMed
P.126 掲載の参考文献
1) Lapiere S. Deux cas de psoriasis recidivants a elements evoluant de facon anormalement rapide en quelques jours. Arch Belg Dermatol Syphiligr 1959 ; 15 : 7-12.
 
2) Bazex A, Dupre A, Chiristol B, et al. psoriasis a type d' erytheme circine recidivant de Bloch. Bull Soc Fr Dermatol Syphiligr 1967 ; 74 : 689-95.
PubMed
3) 山本須賀子, 浜口次生. psoriasis a type d' erytheme circine recidivant (再発性環状紅斑様乾癬) の3例. 皮膚臨床 1980 ; 22 : 721-5.
 
4) 三橋善比古. 再発性環状紅斑様乾癬. 飯塚一, 編. 皮膚科診療プラクティス 16. 乾癬にせまる. 東京 : 文光堂 ; 2004. pp203-6.
 
5) 岩月啓氏, 照井正, 小澤明, ほか. 膿疱性乾癬 (汎発型) 診療ガイドライン 2010. 日皮会誌 2010 ; 120 : 815-39.
 
6) 真鍋幸代, 西本正賢, 高岩 尭. 再発性環状紅斑様乾癬. 臨皮 1995 ; 49 : 486-7.
 
7) Guill CL, Hoang MP, Carder KR. Primary annular plaque-type psoriasis. Pediatr Dermatol 2005 ; 22 : 15-8.
PubMed
8) 佐藤俊樹, 佐藤彩子, 松田真弓, ほか. 環状, 花冠状を呈する乾癬. Visual Dermatology 2002 ; 1 : 532-3.
 
P.131 掲載の参考文献
1) Collamer AN, Guerrero KT, Henning JS, et al. Psoriasis skin lesions induced by tumor necrosis factor antagonist therapy : a literature review and potential mechanisms of action. Arthritis Rheum 2008 ; 59 : 996-1001.
PubMed
1) 小林照子, 相原道子, 池澤善郎. 乾癬型薬疹. 池澤善郎, ほか編. 薬疹のすべて-エキスパートにまなぶ診療の実際. 東京 : 南江堂 ; 2008. pp217-21.
 
2) 大沼すみ, 池澤善郎, 西村百合香, ほか. 乾癬型薬疹 自験15例の臨床的検討. 日皮会誌 1999 ; 109 : 1451-60.
 
3) Dika E, Varotti C, Bardazzi F, et al. Drug-induced psoriasis : an evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutan Ocul Toxicol 2006 ; 25 : 1-11.
PubMed
4) Basavaraj KH, Ashok NM, Rashmi R, et al. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol 2010 ; 49 : 1351-61.
PubMed
5) Fry L, Baker BS. Triggering psoriasis : the role of infections and medications. Clin Dermatol 2007 ; 25 : 606-15.
PubMed
6) Rongioletti F, Fiorucci C, Parodi A. Psoriasis induced or aggravated by drugs. J Rheumatol Suppl 2009 ; 83 : 59-61.
PubMed
7) Kim GK, Del Rosso JQ. Drug-provocated psoriasis : Is it drug induced or drug aggravated? J Clin Aesthetic Dermatol 2010 ; 3 : 32-8.
 
8) Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol 2009 ; 23 : 677-83.
PubMed
9) Cohen AD, Kagen M, Friger M, et al. Calcium channel blockers intake and psoriasis : a case-control study. Acta Derm Venereol 2001 ; 81 : 347-9.
PubMed
10) O'Brian M, Koo J. The mechanism of litium and beta-blocker agents in inducing and exacerbating psoriasis. J Drug Dermatol 2006 ; 5 : 426-33.
 
11) Ockenfels HM, Nussbaum G, Schultewolter T, et al. Tyrosine phosphorylation in psoriatic T cells is modulated by drugs that induce or improve psoriasis. Dermatology 1995 ; 191 : 217-25.
PubMed
12) Heng MCY, Heng MK. Beta-adrenoceptor antagonist-induced psoriasiform eruption. Int J Dermatol 1988 ; 27 : 619-27.
 
13) de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007 ; 143 : 223-31.
PubMed
14) Seneshal J, Milpied B, Vergier B, et al. Cytokine imbalance with increased production of interferon-α in psoriasiform eruptions associated with antitumor necrosis factor-α treatment. Br J Dermatol 2009 ; 161 : 1081-8.
 
15) Fiorentino DF. The Yin and Yang of TNF-α inhibition. Arch Dermatol 2007 ; 143 : 233-6.
 
16) Ritchlin C, Tausk F. A medical conundrum : onset of psoriasis in patients receiving anti-tumor necrosis factor agents. Ann Rheum Dis 2006 ; 65 : 1541-4.
 
17) Moustou A-E, Matekovits A, Dessinioti C, et al. Cutaneous side effects of anti-tumor necrosis factor biologic therapy : a clinical review. J Am Acad Dermatol 2009 ; 61 : 486-504.
PubMed
P.137 掲載の参考文献
1) Mallon E, Bunker CB. HIV-associated psoriasis. AIDS Patient Care STDS 2000 ; 14 : 239-46.
PubMed
2) Montazeri A, Kanitakis J, Bazex J. Psoriasis and HIV infection. Int J Dermatol 1996 ; 35 : 475-9.
PubMed
3) Elhed A, Unutmaz D. Th17 cells and HIV infection. Curr Opin HIV AIDS 2010 ; 5 : 146-50.
PubMed
4) 厚生労働省エイズ動向委員会. 平成21年エイズ発生動向年報. 2010.
 
5)日本エイズ学会, 日本臨床検査医学会. 診療におけるHIV-1/2感染症の診断 ガイドライン 2008. 日本エイズ学会誌 2009 ; 11 : 70-2.
 
6) Towers GJ, Hatziioannou T, Cowan S, et al. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med 2003 ; 9 : 1138-43.
PubMed
7) Cullen BR. HIV-1 infection : fooling the gatekeeper. Nat Med 2003 ; 9 : 1112-3.
PubMed
P.141 掲載の参考文献
1) Chamot AM, Benhamou L, Kahn MF, et al. Le syndrome acne pustulose hyperostose osteite (SAPHO). Rev Rhum Mal Osteoartic 1987 ; 54 : 187-96.
 
1) Siau K, Laversuch CJ. SAPHO syndrome in an adult with ulcerative colitis responsive to intravenous pamidronate. Joint Bone Spine 2010 ; 77 : 176-7.
 
2) Sonozaki H, Mitsui H, Miyanaga Y, et al. Clinical features of 53 cases with pustulotic arthro-osteitis. Ann Rheum Dis 1981 ; 40 : 547-53.
PubMed
2) Schilling F, Marker-Hermann E. Chronic recurrent multifocal osteomyelitis in association with chronic inflammatory bowel disease : entheropathic CRMO. Z Rheumatol 2003 : 62 : 527-38.
PubMed
3) Laasonen LS, Karvonen SL, Reunala TL. Bone disease in adolescents with acne fulminans and severe cystic acne : radiologic and scintigraphic finding. AJR Am J Roentgenol 1994 ; 162 : 1161-5.
PubMed
4) Benhamou CL, Enjolras O, Delrieu F, et al. Pseudoseptic arthritis and bacterid of Andrews. Rev Rhum Mal Osteoartic 1984 ; 51 : 229-31.
PubMed
5) Heliwell P, Marchesoni A, Peters M, et al. A re-evaluation of the ostearticular manifestations of psoriasis. Br J Rheumatol 1991 ; 30 : 339-45.
 
6) Caravatti M, Wiesli P, Uebelhart D, et al. Coincidence of Behcet's disease and SAPHO syndrome. Clin Rheumatol 2002 ; 21 : 324-7.
PubMed
7) Yabe H, Ohshima H, Takano Y, et al. Mucosal lesions may be a minor complication of SAPHO syndrome : a study of 11 Japanese patients with SAPHO syndrome. Rheumatol Int 2010 ; 30 : 1277-83.
PubMed
8) Hayem G, Bouchaud-Chabot A, Benali K, et al. SAPHO syndrome : a long-term follow-up study of 120 cases. Semin Arthritis Rheum 1999 ; 29 : 159-71.
PubMed
9) Salles M, Olive A, Perez-Andres R, et al. The SAPHO syndrome : a clinical and imaging study. Clin Rheumatol 2011 ; 30 : 245-9.
PubMed
10) Earwaker JW, Cotton A. SAPHO : syndrome or concept? Imaging findings. Skeletal Radiol 2003 ; 32 : 311-27.
PubMed
11) Reith JD, Bauer TW, Schils JP. Osseous manifestations of SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome. Am J Surg Pathol 1996 ; 20 : 1368-77.
PubMed
12) Colina M, La Corte R, Trotta F. Sustained remission of SAPHO syndrome with pamidronate : a follow-up of fourteen cases and a review of the literatura. Clin Exp Rheumatol 2009 ; 27 : 112-5.
 
13) Hayama K, Inadomi T, Fujisawa D, et al. A pilot study of medium-dose cyclosporine for the treatment of palmoplantar pustulosis complicated with pustulotic arthro-osteitis. Eur J Dermatol 2010 ; 20 : 758-62.
PubMed
14) Moll C, Hernandez MV, Canete JD, et al. Ilium osteitis as the main manifestation of the SAPHO syndrome : response to infliximab therapy and review of the literature. Semin Arthritis Rheum 2008 ; 37 : 299-306.
PubMed
15) Rozin AP, Nahir AM. Is SAPHO syndrome a target for antibiotic therapy? Clin Rheumatol 2007 ; 26 : 817-20.
PubMed
16) Beretta-Piccoli BC, Sauvain MJ, Gal I, et al. Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome in childhood : a report of ten cases and review of the literature. Eur J Pediatr 2000 ; 159 : 594-601.
PubMed
17) Kahn MF. Why the "SAPHO" syndrome? J Rheumatol 1995 : 22 : 2017-9.
PubMed
P.147 掲載の参考文献
1) Griffiths CEM, Camp RDR, Barker JNWN. Pustular forms of psoriasis. In : Burns T, et al, editors. Rook's Textbook of Dermatology. 7th ed. Oxford : Blackwell Science ; 2004. pp35.54-35.55.
 
2) 戸田憲一. 稽留性肢端皮膚炎. 玉置邦彦, ほか編. 最新皮膚科学大系 6. 水疱症 膿疱症. 東京 : 中山書店 ; 2004. pp255-8.
 
3) 井上雄介, 蒲原毅, 中村和子, ほか. 汎発化をきたしたHallopeau稽留性肢端皮膚炎の1例. 第22回乾癬学会記録集. 2007. pp106-7.
 
4) Wilsmann-Theis D, Hagemann T, Dederer H, et al. Successful treatment of acrodermatitis continua suppurativa with topical tacrolimus 0.1 % ointment. Br J Dermatol 2004 ; 150 : 1194-7.
 
5) Brill TJ, Elshorst-Schmidt T, Valesky EM, et al. Successful treatment of acrodermatitis continua of Hallopeau with sequential combination of calcipotriol and tacrolimus ointments. Dermatology 2005 ; 211 : 351-5.
PubMed
6) Brunasso AM, Lo Scocco G, Massone C. Recalcitrant acrodermatitis continua of Hallopeau treated with calcitriol and tacrolimus 0.1 % topical treatment. J Eur Acad Dermatol Venereol 2008 ; 22 : 1272-3.
 
7) Mang R, Ruzicka T, Stege H. Successful treatment of acrodermatitis continua of Hallopeau by the tumour necrosis factor-alpha inhibitor infliximab (Remicade). Br J Dermatol 2004 ; 150 : 379-80.
PubMed
8) Puig L, Barco D, Vilarrasa E, et al. Treatment of acrodermatitis continua of Hallopeau with TNF-blocking agents : case report and review. Dermatology 2010 ; 220 : 154-8.
PubMed
P.150 掲載の参考文献
1) 松田真弓. 疱疹状膿痂疹. 玉置邦彦, ほか編. 最新皮膚科学大系 18. 全身疾患と皮膚病変. 東京 : 中山書店 ; 2003. pp36-8.
 
2) 岩月啓氏, 照井正, 小澤明, ほか. 膿疱性乾癬 (汎発型) 診療ガイドライン 2010 : TNFα阻害薬を組み入れた治療指針. 日皮会誌 2010 ; 120 : 815-39.
 
3) 沖山良子, 饗場伸作, 金子聡, ほか. 疱疹状膿痂疹. 皮膚病診療 2007 ; 29 : 935-8.
 
4) 赤坂江美子, 梅澤慶紀, 山筋好子, ほか. [薬疹・薬物障害] 疱疹状膿痂疹と鑑別を要した塩酸リトドリンによる膿疱型薬疹の1例. 皮膚臨床 2008 ; 50 : 583-6.
 
5) 谷守, 佐野栄紀, 堤真理. 疱疹状膿痂疹様外観を呈した妊婦自家感作性皮膚炎の1例. 皮膚の科学 2005 ; 4 : 240-3.
 
6) 水芦政人, 徳永英夫, 高橋隼也, ほか. ステロイド内服中の皮疹の再燃に対してNarrow-band UVBが有効であった疱疹状膿痂疹の1例. 皮膚臨床 2010 ; 52 : 225-8.
 
7) Vun YY, Jones B, Al-Mudhaffer M, et al. Generalized pustular psoriasis of pregnancy treated with narrowband UVB and topical steroids. J Am Acad Dermatol 2006 ; 54 : S28-30.
PubMed
8) 鳥居秀嗣. Narrowband UVB療法の適応と限界. 臨皮 2006 ; 60 : 103-7.
 
9) 森田明理. 皮膚科セミナリウム 1. 新しい紫外線療法. 日皮会誌 2005 ; 115 : 1591-7.
 

III 悪化誘因・合併症

P.154 掲載の参考文献
1) Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy : a review and analysis of 127 cases. J Dermatolog Treat 2009 ; 20 : 100-8.
 
1) Comaish JS, Greener JS. The inhibiting effect of soft paraffin on the Kobner response in psoriasis. Br J Dermatol 1976 ; 94 : 195-200.
PubMed
2) Schmid-Ott G, Jaeger B, Boehm T, et al. Immunological effects of stress in psoriasis. Br J Dermatol 2009 ; 160 : 782-5.
PubMed
3) Berg M, Svensson M, Brandberg M, et al. Psoriasis and stress : a prospective study. J Eur Acad Dermatol Venereol 2008 ; 22 : 670-4.
 
4) Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis : a population-based cohort study. Arch Dermatol 2010 ; 146 : 891-5.
PubMed
5) Lewis RS. Using art therapy in the treatment of psoriasis : a pilot study. In : Roenigk HH, et al. editors. Psoriasis. 3rd ed. New York : Marcel Dekker ; 1998. pp815-31.
 
6) Ricketts JR, Rothe MJ, Grant-Kels JM. Nutrition and psoriasis. Clin Dermatol 2010 ; 28 : 615-26.
PubMed
7) Wolters M. Diet and psoriasis : experimental data and clinical evidence. Br J Dermatol 2005 ; 153 : 706-14.
PubMed
8) Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women : Nurses' Health Study II. Am J Med 2007 ; 120 : 953-9.
PubMed
9) Attwa E, Swelam E. Relationship between smoking-induced oxidative stress and the clinical severity of psoriasis. J Eur Acad Dermatol Venereol 2011 ; 25 : 782-7.
PubMed
10) Farkas A, Kemeny L. Psoriasis and alcohol : is cutaneous ethanol one of the missing links? Br J Dermatol 2010 ; 162 : 711-6.
PubMed
11) Ockenfels HM, Nussbaum G, Schultewolter T, et al. Tyrosine phosphorylation in psoriasis T cells is modified by drugs that induce or improve psoriasis. Dermatology 1995 ; 191 : 217-25.
PubMed
12) Ockenfels HM, Wagner SN, Klim-Maas C, et al. Lithium and psoriasis : cytokine modulation of cultured lymphocytes and psoriatic keratinocytes by lithium. Arch Dermatol Res 1996 ; 288 : 173-8.
 
13) Forster S, Ilderton E, Summerly R, et al. The level of phospholipase A2 activity is raised in uninvolved epidermis of psoriasis. Br J Dermatol 1983 ; 108 : 103-5.
PubMed
14) Powles AV, Baker BS, Rutman AJ, et al. Epidermal rupture is the initiating factor for the Koebner response in psoriasis. Acta Derm Venereol 1990 ; 70 : 35-8.
PubMed
15) Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy : a review and analysis of 127 cases. J Dermatolog Treat 2009 ; 20 : 100-8.
 
16) Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy : a literature review and potential mechanisms of action. Arthritis Rheum 2008 ; 59 : 996-1001.
PubMed
P.159 掲載の参考文献
1) 原渕保明. 病巣感染症と扁桃摘出術の有用性. 日本医事新報 1999 ; 3943 : 37-43.
Medical*Online
2) McFadden JP, Baker BS, Powles AV, et al. Psoriasis and streptococci : the natural selection of psoriasis revisited. Br J Dermatol 2009 ; 160 : 929-37.
PubMed
3) Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B, et al. Streptococcal throat infections and exacerbation of chronic plaque psoriasis : a prospective study. Br J Dermatol 2003 ; 149 : 530-4.
PubMed
4) Owen CM, Chalmers RJ, O'Sullivan T, et al. A systematic review of antistreptococcal interventions for guttate and chronic plaque psoriasis. Br J Dermatol 2001 ; 145 : 886-90.
 
5) Fry L, Powles AV, Corcoran S, et al. HLA Cw* 06 is not essential for streptococcal-induced psoriasis. Br J Dermatol 2006 ; 154 : 850-3.
 
6) Mallbris L, Wolk K, Sanchez F, et al. HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis : a case control study. BMC Dermatol 2009 ; 9 : 5.
PubMed
7) Leung DY, Travers JB, Giorno R, et al. Evidence for a streptococcal superantigendriven process in acute guttate psoriasis. J Clin Invest 1995 ; 96 : 2106-12.
PubMed
8) Davison SC, Allen MH, Mallon E, et al. Contrasting patterns of streptococcal superantigen-induced T-cell proliferation in guttate vs. chronic plaque psoriasis. Br J Dermatol 2001 ; 145 : 245-51.
PubMed
9) 山本良一, 九鬼清典, 林泰弘, ほか. 扁桃病巣感染症の発症機序に関する研究-SCIDマウスへのヒト扁桃リンパ球及びヒト皮膚移植による検討. 日本耳鼻咽喉科学会会報 2000 ; 103 : 796-802.
 
10) 林正樹, 後藤浩伸, 保富宗城, ほか. 扁桃病巣感染症における熱ショック蛋白に関する研究 (第2報). 耳鼻咽喉科免疫アレルギー 2003 ; 21 : 88-9.
Medical*Online
11) Nozawa H, Kishibe K, Takahara M, et al. Expression of cutaneous lymphocyte-associated antigen (CLA) in tonsillar T-cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris (PPP). Clin Immunol 2005 ; 116 : 42-53.
PubMed
12) 形浦昭克. 扁桃病巣感染症の臨床-現状と今後の展望 (解説). 耳鼻咽喉科臨床 2002 ; 95 : 763-72.
 
13) 小林里実. 皮膚疾患における扁桃摘出術の適応を考える. 口腔・咽頭科 2009 ; 22 : 55-9.
Medical*Online
14) 松永義孝, Bae Sangjae, 片山一朗. 掌蹠膿疱症に対するマクロライド療法の臨床応用と表皮角化細胞のケモカイン産生に与えるロキシスロマイシンの影響についての検討. 皮膚の科学 2002 ; 1 (Suppl 1) : 46-9.
 
P.162 掲載の参考文献
1) Kobner H. Zur Atiologie der Psoriasis. Vjschr.-fur Dermatologie und Syphilologie 1876 ; 8 : 559-61.
 
2) 植木宏明. ケブネル現象をめぐって. Visual Dermatology 2009 ; 8 : 14-21.
 
3) Miller RAW. The Koebner phenomenon. Int J Dermatol 1982 ; 21 : 192-7.
 
4) Boyd AS, Neldner KH. The isomorphic response of Koebner. Int J Dermatol 1990 ; 29 : 401-10.
PubMed
5) Eyre RW, Krueger GP. Response to injury of skin involved and uninvolved with psoriasis and its relation to disease activity : Koebner and 'reverse' Koebner reactions. Br J Dermatol 1982 ; 106 : 153-9.
 
6) 植木宏明. 乾癬のケブネル現象. 飯塚一, 編. 皮膚科診療プラクティス 16. 乾癬にせまる. 東京 : 文光堂 ; 2004. pp61-7.
 
7) Kuner N, Hartschuh W, Khan-Durani B. Heinrich Kobner und der "isomorphe Reizeffekt". Geschichte und Uberblick. Hautarzt 2003 ; 54 : 274-8.
PubMed
8) Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica 1974 ; 148 : 1-18.
PubMed
9) Eddy DD, Aschheime E, Farber EM. Experimental analysis of isomorphic (Koebner) response in psoriasis. Arch Dermatol 1964 ; 89 : 579-88.
 
10) Toruniowa B, Jablonska S. Mast cells in the initial stages of psoriasis. Arch Dermatol Res 1988 ; 280 : 189-93.
PubMed
11) Raychaudhuri SP, Jiang WY, Raychaudhuri SK. Revisiting the Koebner phenomenon : role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol 2008 ; 172 : 961-71.
PubMed
12) Pedace FI, Muller SA, Winkelmann RK. The biology of psoriasis. An experimental study of the Koebner phenomenon. Acta Derm Venereol 1969 ; 64 : 390-400.
 
13) Kalayciyan A, Aydemir EH, Kotogyan A. Experimental Koebner phenomenon in patients with psoriasis. Dermatology 2007 ; 215 : 114-7.
PubMed
14) Weiss G, Shemer A, Trau H. The Koebner phenomenon : review of the literature. J Eur Acad Dermatol Venereol 2002 ; 16 : 241-8.
PubMed
15) 瀬戸山充. ケブネル現象と成人T細胞白血病・リンパ腫. Visual Dermatology 2009 ; 8 : 70-1.
 
16) 山崎修, 浅越健治. 採皮部に転移した血管肉腫. Visual Dermatology 2009 ; 8 : 68-9.
 
17) Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol 1991 ; 127 : 871-84.
PubMed
18) Telner P, Fekete Z. The capillary responses in psoriatic skin. J Invest Dermatol 1961 ; 36 : 225-30.
PubMed
19) Henno A, Blacher S, Lambert CA, et al. Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques : an approach of vascular development chronology in psoriasis. J Dermatol Sci 2010 ; 57 : 162-9.
PubMed
20) 塩原哲夫. ケブネル現象とリコール現象ならびに類縁現象の関係. Visual Dermatology 2009 ; 8 : 72-7.
 
21) 佐野栄紀. 表皮角化細胞のStat3シグナル (後編). 西日皮膚 2010 ; 72 : 229-34.
 
22) Stankler L. Blood and tissue factors influencing the Koebner reaction in psoriasis. Br J Dermatol 1969 ; 81 : 207-12.
PubMed
P.169 掲載の参考文献
1) Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008 ; 59 : 295-315.
PubMed
2) Weatherhead S, Robson SC, Reynolds NJ. Management of psoriasis in pregnancy. BMJ 2007 ; 334 : 1218-20.
PubMed
3) Bandoli G, Johnson DL, Jones KL, et al. Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis. Br J Dermatol 2010 ; 163 : 334-9.
PubMed
P.172 掲載の参考文献
1) 五十嵐敦之. 我が国の乾癬. MB Derma 2001 ; 53 : 1-6.
 
2) Sommer DM, Jenisch S, Suchan M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006 ; 298 : 321-8.
PubMed
3) Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. Dermatology 2008 ; 216 : 152-5.
PubMed
4) 早川隆, 桑原佳宏, 桧谷興, ほか. 厳格な血糖コントロールにより尋常性乾癬が治癒した2例. 糖尿病 2008 ; 51 : 557.
 
5) メタボリックシンドローム診断基準検討委員会. メタボリックシンドロームの定義と診断基準. 日本内科学会雑誌 2005 ; 94 : 794-809.
 
6) 下村伊一郎, 船橋徹, 松澤佑次. 肥満の役割-アディポサイトカインの産生異常. 日本内科学会雑誌 2004 ; 93 : 655-61.
 
7) 高橋英俊. 乾癬の新しい病因論 : 肥満との関係. 皮膚アレルギーフロンティア 2009 ; 7 : 171-6.
 
8) 伊藤寿啓, 中川秀己. 乾癬患者におけるメタボリックシンドロームの合併について. Visual Dermatology 2010 ; 9 : 1079-81.
 
9) 木原進士. 脂肪細胞由来因子制御による動脈硬化症治療. 分子心血管病 2003 ; 4 : 393-400.
Medical*Online
10) Gerdes S, Zahl VA, Weichenthal M, et al. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology 2010 ; 220 : 38-43.
PubMed
11) 飯田真美. 喫煙と心血管不全. Life Style Medicine 2008 ; 115 : 118-25.
 
12) Uchimoto S, Tsumura K, Hayash T, et al. Impact of cigarette smoking on the incidence of Type 2 diabetes mellitus in middle-aged Japanese men : the Osaka Health Survey. Diabet Med 1999 ; 16 : 951-55.
 
13) Otsuka F, Kojima S, Maruyoshi H, et al. Smoking cessation is associated with increased plasma adiponectin levels in men. J Cardiol 2009 ; 53 : 219-25.
 
14) 片山茂裕, 宮崎滋, 編. 肥満・メタボリックシンドローム診療ガイダンス. 東京 : メジカルビュー社 ; 2005. pp151-3.
 
P.177 掲載の参考文献
1) 赤塚家雄. リウマチ性疾患 : 痛風. 上田英雄, ほか編. 内科学 III. 東京 : 朝倉書店 ; 1991. pp1132-6.
 
2) Gudjonsson JE, Elder JT. Psoriasis. In : Wolff K, et al. editors. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York : McGraw-Hill ; 2008. pp169-93.
 
3) Goldman M. Uric acid in the etiology of psoriasis. Am J Dermatopathol 1981 ; 3 : 397-404.
PubMed
4) Peserico A, Zanetti G, Padovan S, et al. Relationship between body weight and blood pressure and some metabolic parameters in psoriatic patients. Br J Dermatol 1988 ; 118 : 191-4.
PubMed
5) Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the Nalp3 inflammasome. Nature 2006 ; 440 : 237-41.
PubMed
6) Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008 ; 359 : 1811-21.
PubMed
7) Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, et al. Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2009 ; 39 : 157-62.
PubMed
P.180 掲載の参考文献
1) Foitzik K, Langan EA, Paus R. Prolactin and the skin : a dermatological perspective on an ancient pleiotropic peptide hormone. J Invest Dermatol 2009 ; 129 : 1071-87.
 
1) Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010 ; 130 : 1373-83.
PubMed
2) Foitzik K, Langan EA, Paus R. Prolactin and the skin : a dermatological perspective on an ancient pleiotropic peptide hormone. J Invest Dermatol 2009 ; 129 : 1071-87.
 
3) Chuang E, Molitch ME. Prolactin and autoimmune diseases in humans. Acta Biomed 2007 ; 78 (Suppl 1) : 255-61.
 
4) Widschwendter M, Widschwendter A, Welte T, et al. Retinoic acid modulates prolactin receptor expression and prolactin-induced STAT-5 activation in breast cancer cells in vitro. Br J Cancer 1999 ; 79 : 204-10.
PubMed
5) Dunna SF, Finlay AY. Psoriasis : improvement during and worsening after pregnancy. Br J Dermatol 1989 ; 120 : 584.
PubMed
6) Kanda N, Watanabe S. Prolactin enhances interferon-γ-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. Endocrinology 2007 ; 148 : 2317-25.
 
7) Kanda N, Shibata S, Tada Y, et al. Prolactin enhances basal and IL-17-induced CCL20 production by human keratinocytes. Eur J Immunol 2009 ; 39 : 996-1006.
PubMed
P.187 掲載の参考文献
1) Patel RV, Clark LN, Lebwohl M, et al. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009 ; 60 : 1001-17.
PubMed
1) Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriais. J Invest Dermatol 2006 ; 126 : 2194-201.
 
2) Stern RS, Vakeva LH. Noncutaneous malignant tumors in the PUVA follow-up study : 1975-1996. J Invest Dermatol 1997 ; 108 : 897-900.
PubMed
3) 小林桂子, 森田明理, 辻卓夫. 外用PUVA療法と発癌. 日皮会誌 2002 ; 112 : 1247-51.
 
4) Stern RS, Leibman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. J Natl Cancer Inst 1998 ; 90 : 1278-84.
 
5) Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer : a large-scale epidemiological study. Lancet 1991 ; 338 : 91-3.
 
6) 吉川邦彦, 江藤隆史, 小林仁, ほか. 乾癬のPUVA療法ガイドライン. 日皮会誌 2000 ; 110 : 807-14.
 
7) Hannuksela-Svahn A, Sigurgeirsson B, Pukkala E, et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol 1999 ; 141 : 497-501.
PubMed
8) Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA : a nested cohort study. J Am Acad Dermatol 2003 ; 46 : 644-50.
 
9) Lim JL, Stern RS. High levels of ultraviolet B exposure increase the risk of nonmelanoma skin cancer in psoralen and ultraviolet A-treated patients. J Invest Dermatol 2005 ; 124 : 505-13.
PubMed
10) 安田秀美, 川村邦子, 根本治. Narrowband UVB療法の長期副作用に対するearly follow up data. 日皮会誌 2006 ; 116 : 1467-71.
 
11) Hearn RM, Kerr AC, Rahim KF, et al. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 2008 ; 159 : 931-5.
PubMed
12) Paul C, Tourneau AL, Cayuela JM, et al. Epstein-Barr virus-associated lymphoproliferative disorders during methotrexate therapy for psoriasis. Arch Dermatol 1997 ; 133 : 867-71.
 
13) Stern RS, Laird N. The carcinogenic risk of treatments for severe psriasis. Cancer 1994 ; 73 : 2759-64.
PubMed
14) 中川秀美, 相場節也, 朝比奈昭彦, ほか. シクロスポリンMEPCによる乾癬治療のガイドライン 2004年度版 コンセンサス会議報告. 日皮会誌 2004 ; 114 : 1093-105.
 
15) Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin : nested cohort crossover study. Lancet 2001 ; 358 : 1042-5.
PubMed
16) Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine : a 5 y cohort study. J Invest Dermatol 2003 ; 120 : 211-6.
PubMed
17) Vakeva L, Reitamo S, Pukkala E, et al. Long-term follow-up of cancer risk in patients treated with short-term cyclosporine. Acta Derm Venereol 2008 ; 88 : 117-20.
PubMed
18) 筬井泰江, 廣崎邦紀, 嵯峨賢次, ほか. シクロスポリン投与中に悪性リンパ腫を発生した尋常性乾癬の1例. 皮膚臨床 2010 ; 52 : 711-4.
 
19) 大槻マミ太郎, 照井正, 小澤明, ほか. 日本皮膚科学会マニュアル 乾癬における生物学的製剤の使用指針および安全対策マニュアル (2011年版). 日皮会誌 2011 ; 121 : 1561-72.
 
20) Esser AC, Abril A, Fayne S, et al. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol 2004 ; 50 : S75-7.
PubMed
21) 五十嵐敦之. 抗IL-12/23抗体の話題. Visual Dermatology 2010 ; 9 : 853-5.
 
P.193 掲載の参考文献
1) 大野重昭, 熊谷直樹. ぶどう膜炎. 増田寛次郎, ほか編. コンパクト眼科学. 東京 : 金原出版 ; 1995. pp2-34.
 
2) 澤口昭一. 眼の構造と機能. 大野重昭, ほか編. 標準眼科学. 第9版. 東京 : 医学書院 ; 2004. p2.
 
3) Lambert JR, Wright V. Eye inflammation in psoriatic arthritis. Ann Rheum Dis 1976 ; 35 : 354-6.
PubMed
4) Chandran NS, Greaves M, Gao F, et al. Psoriasis and the eye : prevalence of eye disease in Singaporean Asian patients with psoriasis. J Dermatol 2007 ; 34 : 805-10.
PubMed
5) Iijima S, Iwata M, Otsuka F. Psoriatic arthritis and hypopyon-iridocyclitis. Possible mechanism of the association of psoriasis and anterior uveitis. Dermatology 1996 ; 193 : 295-9.
PubMed
6) Durrani K, Foster CS. Psoriasis Uveitis : a distinct clinical Entity? Am J Ophthalmol 2005 ; 139 : 106-11.
PubMed
7) Keino H, Sakai J, Usui M. Association between HLA-A2 in Japanese psoriasis arthritis and susceptibility to uveitis. Graefes Arch Clin Exp Ophthalmol 2003 ; 241 : 777-8.
PubMed
8) 五嶋摩理, 氏原弘, 松原正男. 抗TNFαモノクローナル抗体を使用した乾癬性汎ぶどう膜炎の1例. 臨眼 2010 ; 64 : 1165-8.
 
9) Huynh N, Cervantes-Castaneda RA, Bhat P, et al. Biologic response modifier therapy for psoriatic ocular inflammatory disease. Ocul Immunol Inflamm 2008 ; 16 : 89-93.
PubMed
P.195 掲載の参考文献
1) 中野由美子, 川筋綾子, 筒井清広. 熱中症を契機に水疱性類天疱瘡を発症した尋常性乾癬. 臨皮 2010 ; 64 : 559-62.
 
1) Dainichi T, Kurono S, Ohyama B, et al. Anti-laminin gamma-1 pemphigoid. Proc Natl Acad Sci U S A 2009 ; 106 : 2800-5.
PubMed
2) Chen KR, Shimizu S, Miyakawa S, et al. Coexistence of psoriasis and an unusual IgG-mediated subepidermal bullous dermatosis : identification of a novel 200-kDa lower lamina lucida target antigen. Br J Dermatol 1996 ; 134 : 340-6.
 
3) Zillikens D, Ishiko A, Jonkman MF, et al. Autoantibodies in anti-p200 pemphigoid stain skin lacking laminin 5 and type VII collagen. Br J Dermatol 2000 ; 143 : 1043-9.
PubMed
4) 小林里美. 乾癬に合併する疾患-膠原病と自己免疫性水疱症. MB Derma 2007 ; 126 : 53-61.
 
5) 橋本隆. 類天疱瘡の新たな抗体検査について. 皮膚臨床 2009 ; 51 : 259-66.
 
6) 加藤典子, 水野可魚, 岡本祐之, ほか. 尋常性乾癬に合併した抗p200類天疱瘡. 皮膚臨床 2010 ; 52 : 669-72.
 
7) 浦部由佳里, 藤山幹子, 白方裕司, ほか. 尋常性乾癬に尋常性天疱瘡を合併した1例-カポジ水痘様発疹症が天疱瘡診断の契機となった1例. 日皮会誌 2010 ; 120 : 3109-14.
 
8) Daulat S, Detweiler JG, Pandya AG. Development of pemphigus vulgaris in a patient with psoriasis treated with etanercept. J Eur Acad Dermatol Venereol 2009 ; 23 : 483-4.
 
9) Monnie-Murina K, Du Thanh A, Merlet-Albran S, et al. Bullous pemphigoid occurring during efalizumab treatment for psoriasis : a paradoxical auto-immune reaction? Dermatology 2009 ; 219 : 89-90.
 
P.199 掲載の参考文献
1) Cookson WO, Ubhi B, Lawrence R, et al. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat Genet 2001 ; 27 : 372-3.
PubMed
2) Morar N, Bowcock AM, Harper JI, et al. Investigation of the chromosome 17q25 PSORS2 locus in atopic dermatitis. J Invest Dermatol 2006 ; 126 : 603-6.
PubMed
3) Naldi L, Parazzini F, Gallus S. Prevalence of atopic dermatitis in Italian schoolchildren : factors affecting its variation. Acta Derm Venereol 2009 ; 89 : 122-5.
PubMed
4) Garofalo L, Pisani V, Mazzotta F, et al. Psoriasis in atopic children. Acta Derm Venereol Suppl (Stockh) 1989 ; 146 : 63-5.
PubMed
5) Griffiths CE, Christophers E, Barker JN, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007 ; 156 : 258-62.
PubMed
6) 古江増隆, 佐伯秀久, 古川福実, ほか. アトピー性皮膚炎診療ガイドライン. 日皮会誌 2009 ; 119 : 1515-34.
 
7) Happle R. Linear psoriasis and ILVEN : is lumping or splitting appropriate? Dermatology 2006 ; 212 : 101-2.
PubMed
8) Arnold AW, Happle R, Itin PH. Superimposed linear psoriasis unmasked by therapy with adalimumab. Eur J Dermatol 2010 ; 20 : 573-4.
PubMed
P.203 掲載の参考文献
1) Yamamoto T, Katayama I, Nishioka K. Overlapping cases of psoriasis and Sjogren syndrome ; a study of lymphocyte response to staphylococcal enterotoxin B. J Dermatol Sci 1996 ; 13 : 212-8.
PubMed
2) Yamamoto T, Katayama I, Nishioka K. A rare association of systemic sclerosis and psoriasis vulgaris. J Dermatol 2000 ; 27 : 346-9.
PubMed
3) Yamamoto T. Psoriatic disease with systemic manifestations. J Clin Dermatol 2010 ; 1 : 1-6.
 
4) 川上佳夫, 西部明子, 大塚幹夫, ほか. 関節リウマチを伴った乾癬性紅皮症の1例. 臨皮 2008 ; 62 : 362-5.
 

IV 治療

P.208 掲載の参考文献
1) Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis : section 6. guidelines of care for the treatment of psoriasis and psoriatic arthritis : case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011 ; 65 : 137-74.
PubMed
1) 中川秀己, 相場節也, 朝比奈昭彦, ほか. シクロスポリンMEPCによる乾癬治療のガイドライン 2004年版. コンセンサス会議報告. 日皮会誌 2004 ; 114 : 1093-105.
 
2) Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005 ; 152 : 861-7.
PubMed
2) Nast A, Boehncke WH, Mrowietz U, et al. S3-guidelines on the treatment of psoriasis vulgaris : update 2011. J Dtsch Dermatol Ges 2011 ; 9 (Suppl 2) : S1-95.
 
3) 小林仁, 中川秀己. 乾癬 : 患者QOLに根ざした治療法の選択. 日皮会誌 1999 ; 109 : 1874-80.
 
3) Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012 ; 148 : 95-102.
PubMed
4) Reich K, Burden AD, Eaton JN, et al. Efficacy of biologics in the treatment of moderate to severe psoriasis : a network meta-analysis of randomized controlled trials. Br J Dermatol 2012 ; 166 : 179-88.
PubMed
4) 飯塚一. 乾癬治療のピラミッド計画. 日皮会誌 2006 ; 116 : 1285-94.
 
5) Lucka TC, Pathirana D, Sammain A, et al. Efficacy of systemic therapies for moderate-to-severe psoriasis : a systematic review and meta-analysis of longterm treatment. J Eur Acad Dermatol Venereol 2012 [Epub ahead of print].
 
5) 森田明理. 乾癬治療における光線治療の進歩. 日皮会誌 2006 ; 116 : 1899-903.
 
6) 梅澤慶紀, 小澤明. 患者QOL, 治療アドヒアランスに基づく乾癬治療アルゴリズムの提言. 日皮会誌 2008 ; 118 : 375-84.
 
6) 大槻マミ太郎. 新しい分子標的薬のトピックス. Jak阻害薬の話題. J Visual Dermatol 2010 ; 9 : 861-3.
 
7) 大槻マミ太郎, 照井正, 小澤明, ほか. 日本皮膚科学会マニュアル 乾癬における生物学的製剤の使用指針および安全対策マニュアル (2011年版). 日皮会誌 2011 ; 121 : 1561-72.
 
8) Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis : a population-based study. Arthritis Rheum 2009 ; 61 : 233-9.
PubMed
9) Takata T, Taniguchi Y, Ohnishi T, et al. 18 FDG-PET/CT is a powerful tool for detecting subclinical arthritis in patients with psoriatic arthritis and/or psoriasis vulgaris. J Dermatol Sci 2011 ; 64 : 144-7.
PubMed
10) Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009 ; 161 : 987-1019.
PubMed
11) Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis : section 1. overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 ; 58 : 826-50.
PubMed
12) Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006 ; 296 : 1735-41.
PubMed
13) Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis : results from a population-based study. Arch Dermatol 2007 ; 143 : 1493-9.
PubMed
14) Boehncke WH, Boehncke S, Tobin AM, et al. The'psoriatic march' : a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011 ; 20 : 303-7.
 
15) Ortonne JP, Chimenti S, Reich K, et al. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumor necrosis factor agents : subanalysis of BELIEVE. J Eur Acad Dermatol Venereol 2011 ; 25 : 1012-1020.
PubMed
16) Clemmensen A, Spon M, Skov L, et al. Responses to ustekinumab in the anti-TNF agent-naive vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2011 ; 25 : 1037-40.
PubMed
17) Strober B, Berger E, Cather J, et al. A series of critically challenging case scenarios in moderate to severe psoriasis : a Delphi consensus approach. J Am Acad Dermatol 2009 ; 61 : S1-46.
PubMed
18) 大槻マミ太郎. 乾癬に対するTNF-αアンタゴニストによる治療. MB Derma 2010 ; 169 : 15-27.
 
19) Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009 ; 23 (Suppl 2) : 5-70.
 
20) Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis : a European consensus. Arch Dermatol Res 2011 ; 303 : 1-10.
PubMed
P.218 掲載の参考文献
1) Scholtz JR. Topical therapy of psoriasis with fluocinolone acetonide. Arch Dermatol 1961 ; 84 : 1029-30.
PubMed
2) 堀川達弥. 抗アレルギー剤の使い方 ステロイド外用剤. 医薬ジャーナル 1998 ; 34 : 423-30.
 
3) Koo J, Liao W. Update on psoriasis therapy : a perspective from the USA. Keio J Med 2000 ; 49 : 20-5.
PubMed
4) Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002 ; 205 : 389-93.
PubMed
5) 江藤隆史. ステロイド外用剤の使い方-混合の是非. 臨皮 2001 ; 55 : 96-101.
 
6) 江藤隆史, 大谷道輝. 皮膚外用剤の混合による製剤学的および臨床への影響. 日皮会誌 2004 ; 114 : 2080-7.
 
P.226 掲載の参考文献
1) Naldi L, Rzany B. Psoriasis (chronic plaque). Clin Evid (online) 2009. Jan 9 ; 2009. pii : 1706.
 
1) Simpson RU, DeLuca HF. Characterization of a receptor-like protein for 1,25-dihydroxyvitamin D3 in rat skin. Proc Natl Acad Sci U S A 1980 ; 77 : 5822-6.
PubMed
2) Hosomi J, Hosoi J, Abe E, et al. Regulation of terminal differentiation of cultured mouse epidermal cells by 1α, 25-dihydroxyvitamin D3. Endocrinology 1983 ; 113 : 1950-7.
 
3) Morimoto S, Kumahara Y. A patient with psoriasis cured by 1α-hydroxyvitamin D3. Med J Osaka Univ 1985 ; 35 : 51.
 
4) Morimoto S, Yoshikawa K, Kozuka T, et al. An open study of vitamin D3 treatment in psoriasis vulgaris. Br J Dermatol 1986 ; 115 : 421-9.
PubMed
5) Kragballe K, Beck HI, Sogaard H. Improvement of psoriasis by a topical vitamin D3 analogue (MC903) in a double-blind study. Br J Dermatol 1988 ; 119 : 223-30.
 
6) Smith EL, Walworth NC, Holick MF. Effect of 1α, 25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 1986 ; 86 : 709-14.
 
7) Gerritsen MJ, Rulo HF, Van Vlijmen-Willems I, et al. Topical treatment of psoriatic plaques with 1, 25-dihydroxyvitamin D3 : a cell biological study. Br J Dermatol 1993 ; 128 : 666-73.
PubMed
8) Jeffery LE, Burke F, Mura M, et al. 1, 25-dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009 ; 183 : 5458-67.
PubMed
9) Yamanaka K, Dimitroff CJ, Fuhlbrigge RC, et al. Vitamins A and D are potent inhibitors of cutaneous lymphocyte-associated antigen expression. J Allergy Clin Immunol 2008 ; 121 : 148-57.
 
10) Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris : a multicentre, double-blind, randomized study. Br J Dermatol 1998 ; 138 : 254-8.
 
11) Koo J. How and why to use sequential therapy for psoriasis. Skin Aging 1998 ; 6 : 42-6.
 
12) Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004 ; 150 : 1167-73.
PubMed
13) Poyner T, Hughes IW, Dass BK, et al. Long-term treatment of chronic plaque psoriasis with calcipotriol. J Dermatol Treat 1993 ; 4 : 173-7.
 
P.231 掲載の参考文献
1) 大槻マミ太郎. 外用療法. 玉置邦彦, ほか編. 最新皮膚科学大系 2. 皮膚科治療学皮膚科救急. 東京 : 中山書店 ; 2003. pp29-34.
 
2) Luger T, Paul C. Potential new indications of topical calcineurin inhibitors. Dermatology 2007 ; 215 (Suppl 1) : 45-54.
 
3) 大槻マミ太郎. 乾癬診療 2001 ; ビタミンA 酸誘導体外用薬. MB Derma 2001 ; 53 : 32-40.
 
4) Duvic M, Nagpal S, Asano AT, et al. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol 1997 ; 37 (2 Pt 3) : S18-24.
 
5) van de Kerkhof PC. Update on retinoid therapy of psoriasis in : an update on the use of retinoids in dermatology. Dermatol Ther 2006 ; 19 : 252-63.
 
6) Lebwohl M, Ast E, Callen JP, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998 ; 38 : 705-11.
PubMed
P.234 掲載の参考文献
1) 大槻マミ太郎. 乾癬診療 2001 ビタミンA酸誘導体外用薬. MB Derma 2001 ; 53 : 32-40.
 
2) 都筑有希子. レチノイド, チガソン(R). 手塚正, ほか監. 21世紀の乾癬とその治療. 東京 : トッパンメディカルコミュニケーションズ ; 2002. pp174-9.
 
3) 清島真理子, 北島康雄. レチノイド-乾癬に対する作用機序と臨床効果. 東京 : トッパンメディカルコミュニケーションズ ; 2002. pp88-93.
 
4) 岡田奈津子. レチノイド. 飯塚一, 編. 皮膚科診療プラクティス 16. 乾癬にせまる. 東京 : 文光堂 ; 2004, pp120-4.
 
5) 高橋英俊. 乾癬の治療-ビタミンD3とレチノイド. MB Derma 2007 ; 126 : 47-51.
 
P.237 掲載の参考文献
1) 大槻マミ太郎. 免疫抑制外用薬. 玉置邦彦, ほか編. 最新皮膚科学大系 2. 皮膚科治療学 皮膚科救急. 東京 : 中山書店 ; 2003. pp29-34.
 
1) 高橋英俊, 辻ひとみ, 飯塚一. 重症・中等症乾癬に対するネオーラル(R) 寛解導入療法における至適投与方法の検討-1日1回投与法と1日2回投与法の比較検討. 西日皮膚 2009 ; 71 : 63-9.
 
2) 梅澤慶紀, 赤坂江美子, 馬渕智生, ほか. 乾癬の免疫抑制薬治療における薬物動態に基づいた治療法の確立. 今日の移植 2003 ; 16 : 609-11.
Medical*Online
2) 中川秀己, 五十嵐敦之, 江藤隆史, ほか. 乾癬における患者満足度調査 (第二報) -患者満足度に影響を及ぼす因子の検討. 日皮会誌 2005 ; 115 : 1449-59.
 
3) 大久保ゆかり, 荒井佳恵, 藤原尚子, ほか. Skindex-16/GHQ-28を用いた乾癬患者に対するQOL評価と治療満足度調査. 日皮会誌 2007 ; 117 : 2495-505.
 
3) Hashizume H, Ito T, Yagi H, et al. Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral(R)) in patients with psoriasis vulgaris. J Dermatol 2007 ; 34 : 430-4.
 
4) 中川秀己, 相場節也, 朝比奈昭彦, ほか. シクロスポリンMEPCによる乾癬治療のガイドライン 2004年度版 コンセンサス会議報告. 日皮会誌 2004 ; 114 : 1093-105.
 
4) Umezawa Y, Mabuchi T, Ozawa A. Preprandial vs. postprandial pharmacokinetics of cyclosporine in patients with psoriasis. Int J Dermatol 2007 ; 46 : 880-2.
PubMed
5) 梅澤慶紀, 大井綱郎, 古賀道之. 尋常性乾癬におけるシクロスポリン 1.5mg/kg 1日1回内服法とステロイド外用療法併用の臨床効果についての検討. 日皮会誌 1998 ; 108 : 1965-9.
 
5) Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology : Part I. J Am Acad Dermatol 2010 ; 63 : 925-46.
 
6) 今福信一, 中山樹一郎. 乾癬のシクロスポリン 1.2mg/kg 内服療法. 西日皮膚 2008 ; 70 : 436-41.
 
6) Pathirana D, Ormerod AD, Saiag P, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. JEADV 2009 ; 23 (Suppl 2) : 5-70.
 
7) Rosmarin DM, Lebwohl M, Elewski BE, et al. Cyclosprine and psoriasis : 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2010 ; 62 : 838-53.
 
7) 菅井順一, 平嶋海帆, 大槻マミ太郎. 軽症から中等症の乾癬患者における低用量ネオーラル内服療法の有用性とQOL改善の検討. 日臨皮 2007 ; 24 : 448-52.
 
8) Ho VC, Griffiths CE, Berth-Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis : a 2-year cohort study. J Am Acad Dermatol 2001 ; 44 : 643-51.
 
8) Shintani Y, Kaneko N, Furuhashi T, et al. Safety and efficacy of a fixed-dose cyclosporine microemulsion (100 mg) for the treatment of psoriasis. J Dermatol 2011 ; 38 : 1-7.
PubMed
9) 矢口均, 池田志斈, 小川秀興. 乾癬に対するシクロスポリンの間歇的維持療法. MB Derma 2004 ; 84 : 6-12.
 
9) Ozawa A, Sugai J, Ohkido M, et al. Cyclosporin in psoriasis : continuous monotherapy versus intermittent long-term therapy. Eur J Dermatol 1999 ; 9 : 218-23.
PubMed
10) Okubo Y, Natsume S, Usui K, et al. Low-dose, short-term ciclosporin (Neoral(R)) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients. J Dermatol 2011 ; 38 : 465-72.
 
10) Chaidemenos GC, Mourellou O, Avgoustinaki N, et al. Intermittent vs continuous 1-year cyclosporine use in chronic plaque psoriasis. JEADV 2007 ; 21 : 1203-8.
PubMed
11) Ryan C, Amor KT, Menter A, et al. The use of cyclosporine in dermatology : Part II. J Am Acad Dermatol 2010 ; 63 : 949-72.
 
11) Abe M, Syuto T, Yokoyama Y, et al. Improvement of quality of life and clinical usefulness of cyclosporine administration in patients with nail psoriasis. J Dermatol 2011 ; 38 : 916-8.
PubMed
12) 梅澤慶紀, 小澤明. 乾癬のシクロポリン療法におけるTDM (therapeutic drug monitoring) に基づく治療方針の検討. 臨皮 2004 ; 58 : 96-100.
 
12) 大槻マミ太郎, 照井正, 小澤明, ほか. 乾癬における生物学的製剤の使用指針および安全対策マニュアル (2011年版). 日皮会誌 2011 ; 121 : 1561-72.
 
13) 中川秀己. 皮膚科でよく使う薬剤と妊娠 6. シクロスポリン. 皮膚臨床 1996 ; 38 : 1199-201.
 
14) Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine : a 5 y cohort study. J Invest Dermatol 2003 ; 120 : 211-5.
PubMed
15) Ohtsuki M, Nakagawa H, Sugai J, et al. Long-term continuous versus intermittent cyclosporine : therapy for psoriasis. J Dermatol 2003 ; 30 : 290-8.
PubMed
P.246 掲載の参考文献
1) 大河原章. Methotrexateと乾癬の治療. 皮膚臨床 1978 ; 20 : 789-94.
 
2) Roenigk HH, Auerbach R, Maibach H, et al. Methotorexate in psoriasis : in consensus conference. J Am Acad Dermatol 1998 ; 38 : 478-85.
 
3) Bansback N, Sizto S, Sun H, et al. Efficacy of systemic treatments for moderate to severe plaque psoriasis : systematic review and meta-analysis. Dermatology 2009 ; 219 : 209-18.
PubMed
4) Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis : section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009 ; 61 : 451-85.
PubMed
5) Helliwell PS, Taylor WJ, CASPAR Study Group. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs - comparison of drugs and adverse reactions. J Rheumatol 2008 ; 35 : 472-6.
 
6) Salim A, Tan E, Ilchyshyn A. Folic acid supplementation during treatment of psoriasis with methotrexate : a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006 ; 154 : 1169-74.
PubMed
7) Teare JP, Scherman D, Greenfield SM, et al. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 1993 ; 342 : 895-8.
 
8) Chalmers RJ, Kirby B, Smith A, et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving longterm methotrexate : a multicentre audit and health economic analysis. Br J Dermatol 2005 ; 152 : 444-50.
PubMed
9) Barker J, Horn EJ, Lebwohl M, et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients : report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol 2011 ; 25 : 758-64.
PubMed
10) Lindsay K, Fraser AD, Layton A, et al. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology 2009 ; 48 : 569-72.
PubMed
11) Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis : suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994 ; 37 : 316-28.
PubMed
12) Lindsay K, Fraser AD, Layton A, et al. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford) 2009 ; 48 : 569-72.
PubMed
P.250 掲載の参考文献
1) Heiberg MS, Kaufmann C, Rodevand E, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis : 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 2007 ; 66 : 1038-42.
PubMed
1) Helliwell PS, Taylor WJ, CASPAR Study Group. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs-comparison of drugs and adverse reactions. J Rheumatol 2008 ; 35 : 472-6.
 
2) 前島英樹, 田辺健一, 新井達, ほか. 関節症状を伴った乾癬に対するサラゾスルファピリジン腸溶剤の効能と限界. 日皮会誌 2008 ; 118 : 385-96.
 
2) Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis : a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004 ; 50 : 1939-50.
PubMed
3) 伊藤美津子. 抗リウマチ薬 : サラゾスルファピリジン腸溶剤 (アザルフィジンEN(R)). BIO Clinica 2006 ; 21 : 926-31.
 
3) Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalzine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996 ; 39 : 2013-20.
 
4) Steinsson K, Jonsdottir I, Valdimarsson H. Cyclosporin A in psoriatic arthritis : an open study. Ann Rheum Dis 1990 ; 49 : 603-6.
PubMed
5) Lacaille D. Longterm therapy of psoraitic arthritis : intramascular gold or methotorexate? J Rheumatol 2000 ; 27 : 1922-6.
 
6) The European FK 506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 1996 ; 132 : 419-23.
 
7) Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis : section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009 ; 61 : 451-8.
PubMed
P.253 掲載の参考文献
1) 夏秋優. 皮膚科領域における漢方薬の使い方. MB Derma 2007 ; 131 : 1-6.
 
2) 濱田稔夫, 石井正光, 高橋邦明. 乾癬の漢方療法. 皮膚科東洋医学研究会, 編. 皮膚科における漢方治療の現況 6. 東京 : 総合医学社 ; 1995. pp70-7.
 
3) 桜井みち代. 漢方治療が奏効した尋常性乾癬の10症例. 漢方の臨床 2005 ; 52 : 1015-23.
 
4) 飯島正文, 原田昭太郎, 久木田淳. 乾癬のステロイド外用療法における柴苓湯の併用効果の検討. 皮膚科東洋医学研究会, 編. 皮膚科における漢方治療の現況 3. 東京 : 医学書院 ; 1992. pp37-51.
 
P.257 掲載の参考文献
1) 森田明理. 皮膚科最新光線療法マニュアル 光線療法の将来に向けて 新しいナローバンドUVBとUVA1. MB Derma 2006 ; 116 : 1-9.
 
1) 根本治, 川村邦子. 皮膚疾患における光線療法の模索 クリニックにおけるnarrowband UVBとUVA1療法. 日皮会誌 2004 ; 114 : 1517-27.
 
2) Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis : Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 ; 58 : 826-50.
PubMed
P.264 掲載の参考文献
1) 大槻マミ太郎, 照井正, 小澤明, ほか. 乾癬における生物学的製剤の使用指針および安全対策マニュアル. 日皮会誌 2011 ; 121 : 1561-72.
 
2) Bansback N, Sizto S, Sun H, et al. Efficacy of systemic treatments for moderate to severe plaque psoriasis : systematic review and meta-analysis. Dermatology 2009 ; 219 : 209-18.
PubMed
3) Torii H, Nakagawa H ; Japanese Infliximab Study investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010 ; 59 : 40-9.
 
4) Asahina A, Nakagawa H, Etoh T, et al. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis : efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 2010 ; 37 : 299-310.
PubMed
5) Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis : Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 ; 58 : 826-50.
PubMed
6) Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009 ; 161 : 987-1019.
PubMed
7) Strober B, Berger E, Cather J, et al. A series of critically challenging case scenarios in moderate to severe psoriasis : a Delphi consensus approach. J Am Acad Dermatol 2009 ; 61 : S1-46.
PubMed
8) Reich K, Griffiths C, Barker J, et al. Recommendations for the long-term treatment of psoriasis with infliximab : a dermatology expert group consensus. Dermatology 2008 ; 217 : 268-75.
 
9) Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008 ; 67 : 189-94.
PubMed
10) Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy : a literature review and potential mechanisms of action. Arthritis Rheum 2008 ; 59 : 996-1001.
PubMed
11) Gordon KB, Gandhi M. Strategies for treatment with anti-tumor necrosis factor agents in psoriasis : maintaining efficacy and safety for the long haul. Arch Dermatol 2010 ; 146 : 186-8.
 
12) O'Neill JL, Kalb RE. Ustekinumab in the therapy of chronic plaque psoriasis. Biologics 2009 ; 3 : 159-68.
PubMed
13) Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010 ; 362 : 118-28.
PubMed
14) Igarashi A, Kato T, Kato M, et al. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis : long-term results from a phase 2/3 clinical trial. J Dermatol 2012 ; 39 : 242-52.
PubMed
P.269 掲載の参考文献
1) Guttman-Yassky E, Krueger JG. Psoriasis : evolution of pathogenic concepts and new therapies through phases of translational research. Br J Dermatol 2007 ; 158 : 1103-15.
 
2) Saniabadi AR, Hanai H, Takeuchi K, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003 ; 7 : 48-59.
PubMed
3) Kanekura T, Maruyama I, Kanzaki T. Granulocyte and monocyte adsorption apheresis for pyoderma gangrenosum. J Am Acad Dermatol 2002 ; 47 : 320-1.
PubMed
4) Kanekura T, Yoshii N, Yonezawa T, et al. Treatment of pustular psoriasis with granulocyte and monocyte adsorption apheresis. J Am Acad Dermatol 2003 ; 49 : 329-32.
PubMed
5) Kanekura T, Kawabata H, Maruyama I, et al. Treatment of psoriatic arthritis with granulocyte and monocyte adsorption apheresis. J Am Acad Dermatol 2004 ; 50 : 242-6.
PubMed
6) Kanekura T, Gushi A, Iwata M, et al. Treatment of Behcet's disease with granulocyte and monocyte adsorption apheresis. J Am Acad Dermatol 2004 ; 51 : S83-7.
PubMed
7) Kanekura T, Mochitomi Y, Fujimoto S, et al. Granulocyte and monocyte adsorption apheresis for leg ulcers in a patient with rheumatoid arthritis. J Am Acad Dermatol 2005 ; 52 : 1108-9.
 
8) Kanekura T, Yoshii N, Kawahara K, et al. Granulocyte and monocyte adsorption apheresis for cutaneous allergic vasculitis. Ther Apher Dial 2006 ; 10 : 287-90.
PubMed
9) Kanekura T, Hiraishi K, Kawahara K, et al. Granulocyte and monocyte adsorption apheresis (GCAP) for refractory skin diseases caused by activated neutrophils and psoriatic arthritis : evidence that GCAP removes Mac-1-expressing neutrophils. Ther Apher Dial 2006 ; 10 : 247-56.
PubMed
10) Diamond MS, Springer TA. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J Cell Biol 1993 ; 120 : 545-56.
PubMed
11) Hiraishi K, Takeda Y, Shiobara N, et al. Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads : an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorption apheresis. Ther Apher Dial 2003 ; 7 : 334-40.
 
12) Kashiwagi N, Sugimura K, Koiwai H, et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Digest Dis Sci 2002 ; 47 : 1134-41.
 
P.272 掲載の参考文献
1) Avrach WW. Climatotherapy at the Dead Sea. Proceedings of the Second International Symposium on Psoriasis. New York : Yorke Medical Books ; 1976. pp258-61.
 
2) Even-Paz Z, Shani J. The Dead Sea and psoriasis : historical and geographic background. Int J Dermatol 1989 ; 28 : 1-9.
PubMed
3) Seidl V, Harari M. Klimatotherapie am Toten Meer. Prav Rehab 1991 ; 3 : 177-85.
 
4) Abels DJ, Kattan-Byron J. Psoriasis treatment at the Dead Sea : a natural selective ultraviolet phototherapy. J Am Acad Dermatol 1985 ; 12 : 639-43.
 
5) Dawe RS, Yule S, Cameron H, et al. A randomized controlled comparison of the efficacy of Dead Sea salt balneophototherapy vs. narrowband ultraviolet B monotherapy for chronic plaque psoriasis. Br J Dermatol 2005 ; 153 : 613-9.
 
P.276 掲載の参考文献
1) Takahashi H, Nakamura K, Kaneko F, et al. Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002 - 2008. J Dermatol 2011 ; 38 : 1125-9.
PubMed
1) Wolters M. Diet and psoriasis : experimental data and clinical evidence. Br J Dermatol 2005 ; 153 : 706-14.
PubMed
2) Takahashi H, Tsuji H, Takahashi I, et al. Prevalence of obesity/adiposity in Japanese psoriasis patients : adiposity is correlated with the severity of psoriasis. J Dermatol Sci 2009 ; 54 : 61-3.
 
3) Recevic I, Perl A, Barisic-Drusko V, et al. The role of the low energy diet in psoriasis vulgaris treatment. Coll Antropol 2003 ; 27 (Suppl 1) : 41-8.
 
4) 岡部俊一. 乾癬の絶食療法. 皮膚診療 1990 ; 12 : 811-4.
 
5) Lithell H, Bruce A, Gustafsson IB, et al. A fasting and vegetarian diet treatment trial on chronic inflammatory disorders. Acta Derm Venereol (Stockh) 1983 ; 63 : 397-403.
PubMed
6) Bittiner SB, Tucker WF, Cartwright I, et al. A double-blind, randomized, placebocontrolled trial of fish oil in psoriasis. Lancet 1988 ; i (8582) : 378-80.
PubMed
7) Soyland E, Funk J, Rajika G, et al. Effect of dietary supplementation with verylong-chain n-3 fatty acids in patients with psoriasis. N Engl J Med 1993 ; 328 : 1812-6.
 
8) Serwin AB, Wasowicz W, Gromadzinska I, et al. Selenium status in psoriasis and its relation to the duration and severity of the disease. Nutrition 2003 ; 19 : 301-4.
 
9) Kharaeva Z, Gostova E, Luca CD, et al. Clinical and biochemical effects of coenzyme Q10, vitamin E, and selenium supplementation to psoriasis patients. Nutrition 2009 ; 25 : 295-302.
 

V 社会的対応

P.280 掲載の参考文献
1) 森田明理. あいち乾癬患者友の会 (あいかん友の会). 医薬の門 2009 ; 49 : 202-17.
 
2) 江藤隆史. 東京地区乾癬患者友の会 (Psoriasis Patients Association in Tokyo ; PPAT). 医薬の門 2009 ; 49 : 320-3.
 
3) 稲葉匡彦. 乾癬の会 (北海道). 医薬の門 2009 ; 49 : 380-4.
 
4) 東山真里. 大阪乾癬友の会 (梯の会). 医薬の門 2009 ; 49 : 490-5.
 
5) 谷口芳記. 三重県乾癬の会. 医薬の門 2010 ; 50 : 58-62.
 
6) 白崎文朗. 北陸乾癬の会. 医薬の門 2010 ; 50 : 110-5.
 
7) 佐藤俊宏. 大分乾癬の会. 医薬の門 2010 ; 50 : 208-12.
 
8) 江藤隆史, 森田明理, 安部正敏. 乾癬患者会の今後について考える. 医薬の門 2010 ; 50 : 294-300.
 
9) 橋本秀樹. 山形乾癬友の会 (つばさ). 医薬の門 2010 ; 50 : 384-9.
 
P.286 掲載の参考文献
1) 窪島誠一郎. かいかい日記-「乾癬」と「無言館」と「私」. 東京 : 平凡社 ; 2008.
 
1) Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004 ; 9 : 136-9.
 
2) 岡部伸雄. 豊富町での吾が6年の歳月-仲間と共に過ごした湯快宿での2,130日 (私家版).
 
2) 安田秀美, 小林仁, 大河原章. 乾癬の社会的・精神的影響に関する調査. 日皮会誌 1990 ; 100 : 1167-71.
 
3) 根本治, 中川秀己, 五十嵐敦之, ほか. 乾癬患者における治療満足度調査. 日皮会誌 2003 ; 113 : 2059-69.
 
4) 筒井末春, 橋本加代子. 心身医学からみた皮膚疾患. 東京 : 新興医学出版社 ; 1997. pp40-4.
 
5) 小林仁. 乾癬. 宮路良樹, ほか編. 皮膚心療内科. 東京 : 診断と治療社 ; 2006. pp154-63.
 
6) Gupta MA, Gupta AK, Watteel GN. Early onset (< 40 years age) psoriasis is comorbid with greater psychopathology than late onset psoriasis : a study of 137 patients. Acta Derm Venereol 1996 ; 76 : 464-6.
PubMed
7) Niemeier V, Fritz J, Kupfer J, et al. Aggressive verbal behaviour as a function of experimentally induced anger in persons with psoriasis. Eur J Dermatol 1999 ; 9 : 555-8.
PubMed
8) Conrad R, Geiser F, Haidl G, et al. Relationship between anger and pruritus perception in patients with chronic idiopathic urticaria and psoriasis. J Eur Acad Dermatol Venereol 2008 ; 22 : 1062-9.
PubMed
9) Howard P. Is Psoriasis an angry man's game? http://www.afroarticles.com/article-dashboard/Article/Is-Psoriasis-an-angry-mans--game-/131641. posted on 2008-10-14.
 
10) Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998 ; 139 : 846-50.
PubMed
11) The International Federation of Psoriasis Associations. http://www.ifpa-pso.org/t1.aspx
 

書評

最近チェックした商品履歴

Loading...